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door 
Tialda Hoekstra 
1. Het verbeteren van het fysiek functioneren bij patienten met hartfalen leidt niet alleen tot een betere kwaliteit van !even, maar ook tot een kleinere kans op het hebben van seksuele problemen en overlijden. (Dit proefsclmft) 
2. In tegenstelling tot wat de huidige literatuur doet vermoeden, zijn het niet alleen de mannen met hartfalen die seksuele problemen ervaren. (Dit proefschrift) 
3. De seksuele behoefte van patienten met hartfalen is een taboe. (Dit proefschrift) 
4. Zolang patienten denken dat hartfalen de veroorzaker is van hun seksuele problemen, dienen hulpverleners seksualiteit met hen te bespreken, ongeacht of de veronderstelling klopt. (Dit proefschrift) 
5. Een vergelijkbaar slechte kwaliteit van !even is een van de weinige overeenkomsten tussen patienten met hartfalen en een behouden en een verrninderde linker ventrikel ejectie fractie. (Dit proefschrift) 
6. Brain natriuretische peptide (BNP) als marker voor de ernst van hartfalen is bij patienten met hartfalen en een behouden linker ventrikel ejectie fractie discutabel. (Dit 
proefschrift) 
7. Een stelling is gemakkelijker te weerleggen clan op te stellen. (Aristotelu) 
8. Naast sport, zouden werkgevers ook muziek maken en toneel spelen bij hun werknemers moeten stimuleren om de kans op burn-out te verlagen. 
9. Resultaten op de golfbaan zijn gerelateerd aan zowel het fysiek als het emotioneel functioneren van de golfer. 
10. Accepteren is meer clan ja zeggen. 
11. Het verdient aanbeveling te onderzoeken hoe het mogelijk is dat veel mensen, die gewoon twee oren en een mond hebben, toch functioneren alsof die verhouding net andersom is. 
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Introduction and aims of the thesis 
Current research on (non)pharmacological therapies and devices for patients with 
heart failure has shown that such measures are effective in decreasing mortality 
and readmission rates. Success in prolonging survival in combination with 
increased aging of the general population, will lead to a dramatic increase in the 
prevalence of patients living with heart failure. 1 Although patients live longer 
nowadays, heart failure strongly affects the quality of their lives, which is worse 
compared with healthy elderly subjects, the general population, and patients 
suffering from other chronic disorders.2·4 In recent years, patient preferences and 
patient centred outcomes, such as quality of life, have become of greater 
importance, particularly because life expectancies for patients with heart failure 
have increased. Consequently, patients have to adjust to living with a chronic 
condition. It is interesting to note that for many (elderly) patients, quality of life 
appears to be more important than longer survival. 1,; Fortunately, improving 
quality of life is recognized as one of the major treatment goals in the heart failure 
guidelines of the European Society of Cardiology. 1 Although this recognition has 
resulted in an increase in studies on quality of life of patients with heart failure, 
there are still many gaps in this research area. For example, there is limited 
knowledge of the quality of life of patients with heart failure and a preserved 
ejection fraction (HF-PEF). Sexual health, which forms an important component 
of quality of life of both men and women with cardiovascular disease, has also 
received little attention.6 This thesis intends to address these gaps, and has two 
aims: firstly, to gain more insight in the quality of life of patients with heart failure, 
specifically in patients with HF-PEF, and secondly, to address the sexual health of 
patients with heart failure. 
Chronic heart failure: definition and epidemiology 
Heart failure is generally defined as the inability of the heart to supply sufficient 
blood flow to meet the needs of the body and organs. Heart failure is a chronic 
disease which has the following features: shortness of breath at rest or during 
exertion; fatigue; signs of fluid retention such as pulmonary congestion or ankle 
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swelling; and objective evidence of an abnormality of the structure or function of 
the heart at rest.1 
The most common causes of functional deterioration of the heart are damage to 
the heart muscle or loss of the heart muscle's ability to contract, acute or chronic 
ischemia, increased vascular resistance with hypertension, or the development of a 
tachyarrhythmia such as atrial fibrillation. Coronary heart disease is by far the most 
common cause of myocardial disease, being the initiating cause in about 70% of 
the patients with heart failure.7,8 
Heart failure is one of the most prevalent chronic diseases worldwide, affecting 
between 2 to 3% of the general population. It is even more frequently present in 
the elderly, with a prevalence of 10-20% in people aged 70 years or older. 1 In 
2007, in the Netherlands an average of 6.2 out of a 1000 males, and 8.5 out of a 
1000 females were diagnosed with heart failure. In patients aged 85 years or older, 
the prevalence was even higher: 33.6 per 1000 males, and 40.9 per 1000 females.9 
The overall prevalence of heart failure has increased dramatically over the past 
decades, due to a combination of increased aging of the general population, the 
successful increase in survival in patients suffering from coronary events, and the 
success in postponing coronary events by implementing effective prevention 
measures for those at high risk or those who survived a first coronary event.7,10 
In the past, within the heart failure patient population a distinction was frequently 
made between systolic heart failure and diastolic heart failure. Nowadays, the 
terms heart failure with reduced left ventricular ejection fraction (HF-REF) and 
heart failure with preserved ejection fraction (HF-PEF) are more regularly used 
for both patient populations. Patients with HF-PEF have symptoms and/ or signs 
of heart failure and a preserved left ventricular ejection fraction (L VEF) of >40-
50%. Patients with HF-REF have an LVEF of <40%. 1 Population-based 
epidemiology prevalence studies suggest that almost half of the patients with heart 
failure have HF-PEF. 1 1 ,12 Compared with patients with HF-REF, HF-PEF 
patients are more often older, female, obese, and suffering from diabetes. 11 Due to 
the presence of these co-morbidities, it is often difficult to diagnose heart failure. 
In fact, some patients with assumed HF-PEF do not have heart failure, but suffer 
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from another condition, such as anaerrua, lung disease, or depression.11, 12 To 
account for this difficulty, the guidelines of the European Society of Cardiology 
now state that untreated patients with symptoms of heart failure should have 
plasma levels of B-type natriuretic peptide (BNP) of at least 100pg/ ml to confirm 
the diagnosis of heart failure. 1 The inclusion of this criterion in the guidelines may 
be a first step to make the diagnosis of HF-PEF easier, and to differentiate 
between patients with heart failure and patients with other conditions. For 
instance, due to the implementation of this guideline, patients with heart failure 
symptoms, a preserved ejection fraction and BNP levels <100pg/ml no longer 
meet the HF diagnostic criteria, but rather appear to suffer from another 
condition. 
With respect to BNP levels, it is often assumed that the prevalence of co­
morbidities among patients with low BNP levels is higher than in patients with 
high BNP levels. However, besides their low BNP levels, it is not known how 
these patients differ from patients with HF-PEF and BNP levels >100pg/ml, nor 
is it known how they should be diagnosed and treated. 
Quality of life in patients with heart failure 
The World Health Organisation (WHO) has defined quality of life as 'individuals' 
perception of their position in life in the context of the culture and value systems 
in which they live and in relation to their goals, expectations, standards and 
concerns'. 13 The WHO also states that 'it is a broad ranging concept affected in a 
complex way by the person's physical health, psychological state, level of 
independence, social relationships, personal beliefs and their relationship to salient 
features of their environment'. 13 Although there has been some debate on the 
methods of measuring health-related quality of life, an international group of 
quality of life experts has reached agreement upon health-related quality of life 
assessments. Four dimensions are fundamental to any health-related quality of life 
measure; these include physical, mental/psychological, and social health, as well as 
global perceptions of functioning and well-being. Furthermore, the experts agreed 
that the primary source for health-related quality of life assessment should always 
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be the study participants, or the patients. 14 In this thesis, the words 'quality of life' 
are used when 'health-related quality of life' is meant. Apart from the dimensions 
of quality of life, all aspects are considered together when patients are asked to rate 
'their overall quality of life' or 'overall well-being'. 
In a quality of life assessment a variety of different instruments can be used, 
measuring different components of health. Disease-specific instruments, for 
example, measure symptoms that are specific to the disease being studied, or the 
consequences of the disease on participants' quality of life. These instruments are 
sensitive to subtle disease-specific changes. A disease-specific instrument that is 
often used in heart failure studies is the Minnesota Living with Heart Failure 
questionnaire.15 Disease-generic instruments, on the other hand, measure the 
overall functioning or satisfaction with each area of life, independent of the 
specific disease of the patient. The quality of life of patients in a particular study 
can then be compared with the quality of life of patients with other diseases, such 
as COPD or diabetes. In our study we used the RAND 36-Item Health Survey 
and Cantril's Ladder of Life to measure disease generic quality of life. 16, 17 
Heart failure has a major impact on the physical, mental, and social domains of the 
quality of life of patients.1 , 18 Patients with heart failure have a significantly lower 
quality of life than age- and gender matched members of the community.2 
Compared with other chronically ill patients, the psychical and mental health of 
patients with heart failure is often equally, of even more so, impaired.4 Although it 
is known that heart failure has a negative impact on the length and quality of life 
of patients, 19 studies on whether quality of life in itself has a prognostic power 
with respect to the prediction of mortality are inconsistent.20 Some studies have 
found an association between poorer quality of life and lower survival rates. 
However, inconsistencies may arise from the usage of a limited number or 
different quality of life instruments, and from the variety of follow-up periods, 
ranging from a couple of months till several years.2° Furthermore, it not only 
remains unclear which quality of life dimensions predict mortality best, and in 
order to reduce mortality, which patient-related factors are associated with these 
dimensions. 
Introduction and aims of the thesis I 15 
Nowadays, in the heart failure guidelines, improving quality of life is recognized as 
one of the major treatment goals.1 However, the majority of studies on improving 
treatment outcomes and quality of life have been conducted in patients with HF­
REF. There is only limited knowledge of the quality of life of patients with HF­
PEF compared with patients with HF-REF. This is remarkable, especially 
considering the fact that about 50% of all patients with heart failure have HF­
PEF.11,12 Therefore, it is important to study the quality of life of patients with HF­
PEF. 
Sexual problems in patients with heart failure 
Besides suffering from symptoms that include fatigue and shortness of breath, 
patients with heart failure also have to cope with psychological factors, such as 
depression, low functional capacity, and the need to manage lifestyle changes.2,21·25 
These factors not only affect their overall quality of life, but also their intimacy 
needs.26 Although it is often assumed that sexual activity is not important for 
seriously ill patients, patients with heart failure do consider sexual activity in their 
current condition as an essential aspect of quality of life. Unfortunately, symptoms 
of heart failure affect the sexual relationships of these patients. 6,27,28 At least 50% 
of all patients with heart failure report their sexual activity has decreased or even 
completely ceased as a result of their heart failure. Furthermore, half of the 
patients have problems with sexual activity caused by erectile dysfunction or 
orgasmic problems, and experience sexual dissatisfaction.26 29 Previous research 
has mainly focused on male sexuality and erectile dysfunction.27 However, heart 
failure symptoms like dyspnoea, fatigue, and exercise intolerance can also be 
assumed to affect the sexual health of both male and female patients. Considering 
the demographical characteristics of patients with heart failure in daily practice, in 
which 50% is female and 30-50% is living alone, more in-depth information is 
needed on the problems of both female and male patients.30-32 
At the same time it should not be forgotten that there are age- related changes in 
sexuality, caused by normal hormonal changes, vascular damage, or muscular 
weakness, that are independent of heart failure. This means sexual problems might 
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be part of the aging process and therefore not only caused by heart failure.33 For 
further research on this subject it is important to have insight in the nature and 
cause of sexual problems of patients with heart failure compared with healthy 
members of the community. 
Although the current heart failure guidelines recommend counselling on sexual 
activity to both male and female patients and their partners, previous studies have 
shown that even though healthcare providers do feel responsible for discussing 
sexual health, they rarely discuss this topic with their patients in practice.1-29.34 To 
improve patient care, it is important to know which barriers withhold healthcare 
providers, in particular nurses, from discussing this issue with their patients. Heart 
failure nurses are becoming more and more involved in the long-term 
management of patients with heart failure, and it can be expected that they have 
an increasingly important role to play in discussing sexual health and the 
consequences of heart failure on sexual health with patients and their partners. 
Aims of this thesis 
To gain more insight in the quality of life and the sexual health of patients with 
heart failure, the following aims of this thesis are formulated: 
• To examine the prognostic value of quality of life on long-term survival of 
patients with heart failure. 
• To examine the quality of life of patients with a preserved left ventricular 
ejection fraction in more detail. 
• To assess the prevalence of sexual problems and related factors in patients 
with heart failure. 
• To describe the current practice of discussing sexuality by heart failure 
nurses. 
To accomplish the first three aims, data from the COACH study (Coordinating 
study evaluating Outcomes of Advising and Counselling in Heart failure) are used. 
COACH was a multicenter, randomized clinical trial on the effect of a disease 
management program in heart failure.35, 36 A total of 1023 patients from 17 
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hospitals in the Netherlands were enrolled in the COACH study. Patients were 
included in the study during a hospitalization for heart failure (NYHA functional 
class II to IV),  with heart failure as the primary diagnosis. During hospitalization 
all patients received standard care, both pharmacological and non­
pharmacological, according to the guidelines. 1 After the baseline assessment, 
patients were randomised to either 'care-as-usual', basic support, or intensive 
support, which differed in the intensity of advising and counselling provided. 
Follow-up assessments took place at 1, 6, 12 and 18, months after discharge. 
The first aim of this thesis is addressed by examining the predictive value of three 
different quality of life instruments (general well-being, disease-generic quality of 
life and disease-specific quality of life), on long-term mortality (Chapter 2). 
Chapter 3 addresses the quality of life of patients with HF-PEF compared with 
patients with HF-REF. Chapter 4 specifically focuses on the quality of life of 
patients with HF-PEF, and will compare patients with low BNP levels and high 
BNP levels. 
Chapters 5 and 6 focus on the third aim. In Chapter 5, the prevalence of sexual 
problems is examined by using one question on sexual functioning from the 
Minnesota Living With Heart Failure questionnaire. Patients who perceive 
problems are compared with patients who do not perceive problems on a broad 
range of characteristics and quality of life dimensions. Chapter 6 covers the 
specific problems patients with and without a partner experience with sexuality 
due to their heart failure, compared with healthy community controls. This 
chapter also addresses the differences between younger and older patients with 
respect to sexuality. 
Finally, in Chapter 7 the current practice of discussing sexual health and the 
perceived responsibility of heart failure nurses for addressing this topic are 
described, as are the barriers that prevent them from discussing sexuality with 
their patients. 
Recommendations for clinical practice and future research to improve quality of 
life in patients with heart failure, including discussing sexual health, will be 
described in Chapter 8. 
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Abstract 
Aims: To examine whether self-rated disease specific and generic quality of life 
predicts long-term mortality, independent of brain natriuretic peptide (BNP) 
levels, and to explore factors related to low quality of life, in a well-defined heart 
failure (HF) population. 
Methods: A cohort of 661 patients (62% male; age 71; left ventricular ejection 
fraction 34%) was followed prospectively for 3 years. Quality of life questionnaires 
(Ladder of life, RAND36 and J\.1innesota living with Heart Failure Questionnaire) 
and BNP levels were assessed at discharge after a hospital admission for HF. 
Results: Three-year mortality was 42%. After adjustment for demographic 
variables, clinical variables and BNP levels, poor quality of life scores predicted 
higher mortality; per 10 units on the physical functioning (hazard ratio (HR) 1.08; 
9511/t, confidence interval (CI) 1.02-1.14), and general health (HR 1.08; 95% CI 
1.01-1.16) dimensions of the RAND36. Patients with low scores on these 
dimensions were more likely to be in New York Heart Association class III-IV, 
diagnosed with co-morbidities, have suffered longer from HF, have lower 
estimated glomerular filtration rates, and had fewer beta-blocker prescriptions. 
Conclusion: Quality of life was independently related with survival in a cohort of 
hospitalized patients with HF. 
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1. Introduction 
Heart failure (HF) has a negative impact on the length and quality of life (QoL) of 
patients. 1 ,2 Studies on whether QoL in itself has prognostic power for the 
prediction of mortality are inconsistent. Some, but not all, studies have found an 
association between poorer QoL and worse survival.3 Inconsistencies in previous 
studies may be explained by their using different QoL instruments to predict 
outcomes. Most studies used one questionnaire, or focused on one subscale or 
question from a specific QoL questionnaire. Only a few have used disease-generic 
QoL questionnaires (Short Form-36 (SF-36)) simultaneously with disease-specific 
QoL questionnaires (Minnesota Living with Heart Failure questionnaire 
(MLwHFQ), Kansas City Cardiomyopathy Questionnaire) in their patient 
population to describe the association between QoL and survival in HF patients.3 
Inconsistencies may also arise from the different follow-up periods used in the 
different studies, which ranged from a couple of months to >5 years, and each 
study adjusted for different demographic and clinical variables.4-8 The majority of 
studies did adjust for disease severity by using left ventricular ejection fraction 
(LVEF) or the New York Heart Association (NYHA) functional class.3 However, 
both NYHA and L VEF have limitations as markers for disease severity. L VEF 
only reflects the severity of LV systolic dysfunction and not the severity of HF,9 
whereas NYHA classification is highly subjective based on the endurance of the 
patient and is directly associated with (physical) QoL. Furthermore, the utility of 
NYHA classification used as a marker of disease severity is currently the subject of 
some debate owing to low inter-rater reliability.1 0  Brain natriuretic peptide (BNP) 
has in recent years emerged as a reliable reflection of the severity of HF. 1 1  None of 
the aforementioned studies used BNP as a marker for the severity of HF. 
Provided that QoL is a predictor of mortality, the important next step is to find 
out which patients have a low QoL. In order to reduce mortality, these patients in 
particular could benefit most from additional treatment, focused on improving 
QoL. 
To gain more insight into the prognostic value of QoL, we examined the 
predictive value of several QoL instruments for long-term mortality in a large 
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group of HF patients. In order to control with an objective parameter for the 
severity of HF, we adjusted for plasma levels of BNP in our analyses. Additionally, 
we examined the characteristics of patients with high and low QoL scores. 
2. Methods 
2.1 Patient population 
Data were collected as part of the COACH study (Coordinating study evaluating 
Outcomes of Advising and Counselling in Heart failure) . COACH was a 
multicentre, randomized clinical trial on the effect of a disease management 
programme in HF, the design, main results and first QoL data have been 
published.2, 1 2• 14 In brief, 1023 patients from 17 hospitals in The Netherlands were 
enrolled in the COACH study. Patients were included in the study during a 
hospitalization for HF (NYHA functional class II-IV), with HF as the primary 
diagnosis. The diagnosis was based on a combination of typical signs and 
symptoms according to the European Society of Cardiology (ESC) guidelines 1 5  for 
which a hospital stay was considered necessary. During hospitalization all patients 
received standard care, both pharmacological and non-pharmacological, according 
to the guidelines, 1 5  in a cardiology ward, staffed by cardiologists and registered 
nurses. Patients were 18 years or older and had evidence of structural underlying 
heart disease. Exclusion criteria were: concurrent inclusion in a study requiring 
additional visits to research healthcare personnel; restrictions that made the patient 
unable to fill in data collection forms; an invasive intervention within the last 6 
months or planned during the following 3 months; or ongoing evaluation for heart 
transplantation. All patients gave written informed consent. 
The Central Ethics Committee approved the study protocol and the extended 3-
year follow-up data collection on survival. The study was performed in accordance 
with the principles outlined in the Declaration of Helsinki. 
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2.2 Data collection 
Plasma BNP levels were determined once and analysed locally within 4h of blood 
collection (1 mL of blood, collected in EDTA), on the day of hospital discharge or 
on the day before hospital discharge. All BNP measurements were performed 
using a fluorescence immunoassay kit (Triage ; Biosite Incorporated, San Diego, 
CA, USA). 1 6  Data on left ventricular function were obtained by standard 
transthoracic echocardiography. 
Survival data were collected during the 18-month follow-up period of the 
COACH study as part of the primary endpoint of the study. Cause of death and 
the date of the event were adjudicated by a central end-points committee. 
Concerning the patients who survived the 18-month follow-up period, 3-year 
follow-up (1095 days) data on all-cause mortality were collected from the hospital 
registry, and the general practitioner and/ or municipality, 3 years after the last 
patients was included in the COACH study. For each patient who survived the 
initial 18-month follow-up, but died afterwards, a calculation was made on the 
time period between dying and inclusion in the COACH study in order to have an 
equally long follow-up period for each patient (1095 days). 
Data on QoL were collected during hospitalization. Quality of life was assessed in 
three different ways: global well-being, disease-generic QoL and disease-specific 
QoL. 
Global well-being was assessed by Cantril's Ladder of Life. This is a single-item 
measure which asks the patient to rate their sense of well-being on a ladder, with 
10 reflecting the best possible life imaginable and O reflecting the worst possible 
life imaginable. Cantril's Ladder of Life has been used in various cardiovascular 
studies and is considered to be a valid measure of global well-being. 1 7 A higher 
score indicates better well-being.IS 
Disease-generic QoL was assessed by the Medical Outcome Study 36-item 
General Health Survey (RAND36), a self-report questionnaire of general health 
status and comparable with the Short-Form-36 Health Survey (SF-36).1 9,20 The 
RAND36 is a well-validated generic, 36-item questionnaire that includes nine 
health concepts that represent dimensions of QoL: physical functioning, social 
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functioning, role limitations because of physical functioning, role limitations 
because of emotional functioning, mental health, vitality, bodily pain, general 
health and perceived health change. Each dimension has a score between 0 and 
100; a higher score means better health. 19 
Disease-specific QoL was measured with the Minnesota Living with Heart Failure 
questionnaire (MLwHFQ).2 1  The MLwHFQ is a 21-item scale, with a scoring 
range of zero for no impairment, to 105 for maximum impairment as a result of 
HF. Three scores can be determined: a total score (21 items, 0-105), the physical 
dimension (8 items, 0-40), and the emotional dimension (5 items, 0-25). Higher 
scores mean a worse QoL. The questions cover symptoms and signs relevant to 
HF, e.g. physical activity, social interaction, sexual activity, work and emotions. All 
patients were instructed by trained data collectors to report if, and to what extent 
HF has affected their life during the last month on each item. The reliability and 
validity of the MLwHFQ have been documented.21 
2.3 Statistical analysis 
Descriptive statistics were used to characterize the study population. Data are 
presented as means ± standard deviations (SDs) or percentages. Student's t-tests 
and Mann-\X'hitney tests for continuous variables and Chi2 square tests for 
categorical variables were performed to compare demographic characteristics, 
clinical characteristics and QoL between patients who survived and did not survive 
the 3-year follow-up period. Cox proportional hazards regression was used to 
determine the independent association of QoL with time to mortality. Separate 
analyses were made for each scale: the nine dimensions of the RAND36, both 
subscales and total score of the J\,1LwHFQ and the Ladder of Life. To evaluate a 
possible effect-modifying role of potential risk factors with regard to mortality, 
three Cox regression analyses were performed; first including the QoL scale, 
secondly adjusting for age and gender, and finally adjusting for all variables with a 
theoretical or univariate association with mortality (p-value <0.10 two tailed). 
Within the third model there was no hierarchical inclusion of the variables. All 
variables were entered as dummies except for age, BNP, QoL scales, systolic 
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blood pressure, diastolic blood pressure, heart rate, sodium, and estimated 
glomerular filtration rate (eGFR) which were modelled as continuous variables. 
The RAND36 dimensions and the total score of the MLwHFQ were recoded per 
10 units. To gain hazard ratios (HRs) >1.00 for reasons of readability, the scores 
of the RAND36 dimensions per 10 units and the Ladder of Life scores were 
subtracted from 10. All QoL scales were stratified by centre. 
More in-depth analyses on patient characteristics of the two QoL dimensions with 
the highest prediction on survival were performed. We compared patients who 
scored in the lowest quartiles with patients who scored in the highest quartiles on 
these dimensions. Kaplan-Meier curves with a log-rank test were constructed for 
the patients in the lowest and highest quartiles of both dimensions. Statistical 
significance was set at two-tailed p<0.05. Analyses were performed with STATA 
version 11 (StataCorp., College Station, TX, USA). 
3. Results 
3.1 Patient characteristics 
Of the 1023 patients included in the main COACH study, a BNP-level was 
available in 766 patients. Within the patient sample of 766 patients, all QoL 
questionnaires at baseline were completed by 661 patients (86%). Only patients 
with available BNP levels who completed all questionnaires were included in the 
current study. Patients who were excluded from the current study did not differ 
from the study sample on age, gender, NYHA functional class at discharge, and 
L VEF function. 
Patients had a mean age of 71 years (± 11), 61 % was male and 40% were living 
alone. The mean LVEF was 34% (± 14), 33% had an LVEF >40%, and at 
discharge 51 % were classified as NYHA functional class III-IV (Table 1). During 
the 3-year follow-up, 276 (42%) patients died; no patients were lost to follow-up. 
Patients who died during the follow-up period were significantly older, more often 
in NYHA III-IV, had higher BNP levels at hospital discharge, lower systolic and 
diastolic blood pressure, lower eGFRs, had been diagnosed with HF for longer, 
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were more often previously hospitalized for HF, and were more often diagnosed 
with diabetes or had a stroke in the past than patients who survived the 3-year 
follow-up period. Furthermore, the survivors were more often treated with 
angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers 
(ARBs) and beta-blockers at discharge than the non-survivors (Table 1). 
3.2 Quality of life 
Global well-being at baseline, as measured with Cantril's Ladder of Life, did not 
differ significantly between survivors and non-survivors (6.3 (± 1.7) vs. 6.2 (± 1.9), 
p=0.170). 
Mean scores of all dimensions of the RAND36 in the total group varied between 
18 and 66 on the theoretical range between O and 100, with the lowest scores for 
role limitations physical (18 (± 33)), health change (25 (± 23)), and physical 
functioning (34 (± 26)). Non-survivors had a significantly lower QoL at baseline 
than survivors on the physical functioning (28 (± 23) vs. 39 (± 27), p<0.001), role 
limitations physical (13 (± 27) vs. 22 (± 36), p<0.001), bodily pain (60 (± 34) vs. 
66 (± 34), p=0.031) and general health (41 ± 18 vs. 46 ± 19, p=0.001) dimensions 
(Figure 1). 
The mean score in the total group on the total scale of the MLwHFQ was 44 
(±21). On the physical and emotional subscales, mean scores were 24 ± 23 and 7.1 
± 6.1, respectively. On the MLwHFQ non-survivors rated their QoL at baseline 
significantly lower than survivors on the total score (47 (± 19) vs. 42 (± 22), 
p=0.010) and the physical subscale (25 (± 9) vs. 22 (± 11), p=0.001). The 
emotional subscale scores of the MLwHFQ at baseline did not differ between 
survivors and non-survivors (6.9 (± 6.1) vs. 7.3 (± 6.1), p=0.380). 
Quality of life and sun·n-al in patients with heart failure I 31 
Table 1. Baseline characteristics according to mortality 
Total group Survivors Non-survivors 
p value* 
(n=661) (n=385) (n=276) 
Demographics 
Age (years) 71 ± 1 1  68 ± 1 2  74 ± 1 0  < .001 
Male 62% 58% 64% . 147 
Living alone 40% 39% 42% .336 
Smoking 1 7% 1 8% 1 5% .290 
Clinical characteristics 
LVEF % 34 ± 14 34 ± 14 34 ± 14 .916 
NYHA III-IV 5 1% 45% 59% <.001 
Systolic blood 
1 1 8  ± 21 1 20 ± 21 1 1 6  ± 20 .039 
pressure (mm/Hg) 
Diastolic blood 
69 ± 1 2  70 ± 1 2  66  ± 1 2  <.001 
pressure (mm/Hg) 
Heart rate (6pm) 75 ± 1 3  75  ± 14 74 ± 12  .409 
BNP (pg/mL) 
447 (202-869) 342 (161 -725) 572 (300-1 1 10) < .001 
median (IQR) 
Sodium (mEq/L) 139 ± 4.7 1 39 ± 4.6 1 38 ± 4.9 . 1 86 
eGFR 
57 ± 22 61 ± 22 50 ± 20 < .001 
(ml/min/1 .73m2) 
Hypertension 44% 44% 43% .968 
Ischemic heart 
42% 38% 46% .041 
failure 
Duration of heart 
2.7 ± 4.5 2.0 ± 3.8 3.7 ± 5.1 < .001 
failure (years) 
> 1 previous heart 




84% 87% 81% .030 
inhibitors/ ARB 
Beta-blockers 65% 68% 61% .043 
Diuretics 97% 96% 98% . 1 21 
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Total group Survivors Non-survivors 
(n=661) (n=385) (n=276) 
27% 25% 29% 
28% 23% 34% 
9% 7% 12% 
7% 7% 8% 






Abbreviations: LVEF=left ventricular ejection fraction; NYHA=New York Heart 
Association functional class; BNP=B-type Natriuretic peptide; IQR=Inter 
Quartile Range; eGPR=estimated Glomerular Filtration Rate; ACE=Angiotensin 
Converting Enzyme; ARB=Angiotensin Receptor Blocker; COPD=Chronic 
Obstructive Pulmonary Disease 
• S..vivors (n=385) o Non-si.rvivors (n=276) 
Figure 1. Quality of life as measured by the RAND36 at baseline according 
to mortality. 
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3.3 Survival analyses 
Univariate analyses (model 1) show a HR of 1.15 (95% confidence interval 1.09-
1.21) per 10 units on the physical functioning dimension of the RAND36, which 
indicates an increase of 15% in mortality per 10 units decrease on the physical 
functioning score. Furthermore a decrease in scores per 10 units on the role 
limitations physical, bodily pain, and general health dimensions of the RAND36 
showed a significant increase in mortality (respectively 8%, 4%, and 12%, 
respectively). An increase in score per 10 units on the total score of the MLwHFQ 
and per one unit on the physical functioning score of the MLwHFQ also showed 
a significant increase of 7% and 2% in mortality (Table 2). 
After adjusting the model for age, gender, NYHA, smoking, systolic blood 
pressure, diastolic blood pressure, heart rate, BNP-level, sodium-level, eGFR, 
ischaemic HF, duration of disease, previously hospitalized for HF more than once, 
ACE inhibitors/ ARBs, beta-blockers, diuretics, diabetes, stroke and renal disease 
(model 3), the physical functioning and general health dimensions of the RAND36 
were associated with mortality (Table 2). 
Table 2. Cox proportional hazards regression of the quality of life subscales on time to mortality (n=661) 
Ladder of Lift 
Well-being 
RAND-36 (per 10 units) 
Physical functioning 
Social functioning 
Role limitations Physical 






Minnesota Living 1vith Heart 
Failure questionnaire 
Total (per 10  units) 
Physical functioning 
Emotional functioning 
Model 1 :  no adjustments 
Model 1 
HR (95% CI) 
1 .04 (0.98-1 . 1 1) 
1 . 1 5  (1 .09-1 .21) 
1 .01 (0.97-1 .05) 
1 .08 (1 .03- 1 . 13) 
1 .02 (1 .00-1 .05) 
1 .03 (0.98-1 .08) 
1 .05 (1.00-1 . 1 1) 
1 .04 (1 .00-1 .08) 
1 . 12  (1 .05-1 .20) 
1 .01 (0.96-1 .06) 
1 .07 (1 .02-1 . 13) 
1 .02 (1.01 -1 .03) 
1 .01 (0.99-1 .03) 
















HR (95% CI) 
1 .05 (0.98-1 . 12) 
1 . 1 3  (1 .07-1 .20) 
1 .02 (0. 99-1 .06) 
1 .08 (1 .04-1 . 13) 
1 .02 (1 .00-1 .05) 
1 .06 (1 .00-1 . 1 1) 
1 .07 (1 .02- 1 . 13) 
1 .04 (1 .00-1 .07) 
1 . 1 3  (1 .06-1 .21) 
1 .02 (0.96-1 .07) 
1 . 12  (1 .06- 1 . 19) 
1 .02 (1 .01-1 .03) 
















HR (95% CI) 
1 .01 (0.94-1 .08) 
1 .08 (1.02-1 . 14) 
0.98 (0.95-1 .02) 
1 .04 (0.99-1 .08) 
1 .01 (0.98-1 .04) 
1 .04 (0.99-1 . 10) 
1 .03 (0.98-1 .09) 
1 .03 (0.99-1 .07) 
1 .08 (1 .01 -1 . 1 6) 
1 .00 (0.95-1 .05) 
1 .05 (0.98-1 . 12) 
1 .01 (0.99-1 .02) 















Model 3: adjustment for age, gender, smoking, NYHA, systolic blood pressure, diastolic blood pressure, heart rate, 
BNP-level, sodium-level, eGFR, ischemic heart failure, duration of disease, previously hospitalized for heart failure 
>1 ,  ACE-inhibitors/ ARB, beta-blockers, diuretics, diabetes, stroke and renal disease 
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3.4 Patient characteristics related to low physical functioning and general 
health 
Patient characteristics were compared between patients who scored in the lowest 
quartile of physical functioning (range 0-15) and general health (range 0-30) and 
the highest quartile (ranges respectively 50-100 and 55-100, respectively). Patients 
with a low QoL on physical functioning were older, more often female, more 
often in NYHA III-IV, had higher BNP levels at discharge, lower sodium levels, 
lower diastolic blood pressure, lower eGFRs, were more often diagnosed with 
chronic obstructive pulmonary disease (COPD),  diabetes and stroke, had a longer 
duration of HF, were more often previously hospitalized for HF, and less often 
had a prescription of beta-blockers at discharge, than patients with high physical 
functioning (Table 3). 
Patients with a low QoL on the general health dimension were also more often in 
NYHA III-IV, diagnosed with COPD and stroke, had suffered longer from HF, 
more often previously hospitalized for HF, had lower eGFRs, and were more 
often diagnosed with renal disease than patients with a high QoL on the general 
health dimension (fable 3). 
During the 3-year follow-up period, 84 of the 157 patients (54%) with a low 
physical functioning score, and 39 of the 151 patients (26%) with a high physical 
functioning score, died (p<0.001 )  (Figure 2). Of the 133 patients with a low 
general health score, 75 patients (56%) died, compared to 54 of the 153 patients 
(35%) with a high general health score (p<0.001) (Figure 3). 
Table 3. Patient characteristics; low versus high quality of life 
Low physical High physical Low general High general 
functioning functioning p-value health health p-value 
(n= 1 57) (n= 1 51) (n= 133) (n= 1 53) 
Demographics 
Age (years) 74 ± 1 0  67 ± 1 1  <.001 70 ± 12  72  ± 1 1  .301 
Male 47% 72% <.001 56% 59% .678 
Living alone 46% 36% .079 39% 46% .256 
Smoking 16% 19% .433 12% 1 8% . 1 77 
Clinical charactenstics 
LVEF % 34 ± 15  32  ± 14  .21 9 35 ± 1 5  3 5  ± 1 5  .975 
NYHA III-IV 69% 26% <.001 66% 33% < .001 
Systolic blood 1 17 ± 22 121 ± 21 . 109 1 15 ± 21 1 20 ± 21 .055 pressure (mm/Hg) 
Diastolic blood 67 ± 1 3  7 1  ± 12  .007 68 ± 1 3  70  ± 12  . 103 pressure (mm/Hg) 
Heart rate (6pm) 75 ± 1 3  74 ± 1 4  .474 74 ± 14  73  ± 13  .536 
BNP (pg/ mL) median 497 (244-1090) 348 (162-747) (IQR) .017 502 (232-1 070) 389 (179-801) . 125 
Sodium (mEq/L) 137 ± 5.9 1 39 ± 4.3 < .001 138 ± 5.3 1 39 ± 5.2 .087 
eGFR 51 ± 1 9  62  ± 21 < .001 52 ± 22 58 ± 1 9  .021 (ml/min/1 .73m2) 
Hypertension 47% 42% .399 44% 39% .452 
Ischemic heart failure 39% 40% .874 39% 42% .561 
Table 3. (Continued) Patient characteristics; low versus high quality of life 
Duration of heart 
failure (years) 
> 1 previous heart 
failure hospitalization 
Medication 








Quality of life 
Physical functioning 
General health 
Low physical High physical Low general 
functioning functioning p-value health 
(n=157) (n=151) (n=133) 









6 ± 4  
36 ± 17 









74 ± 15 





















21 ± 19 













50 ± 29 













Abbreviations: LVEF=left ventricular ejection fraction; NYHA=New York Heart Association functional class; 
BNP=B-type Natriuretic peptide; IQR=Inter Quartile Range; eGFR=estimated Glomerular Filtration Rate; 
ACE=Angiotensin Converting Enzyme; ARB=Angiotensin Receptor Blocker; COPD=Chronic Obstructive 
Pulmonary Disease 
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Figure 2. Kaplan-Meier curves for time to death in patients with low 
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Figure 3. Kaplan-Meier curves for time to death in patients with low general 
health and high general health. 
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4. Discussion 
The main finding of the present study is that QoL independently of BNP values 
predicts 3-year mortality in patients with HF. To our knowledge this is the first 
study in a large and clinically  relevant group of HF patients in which the effect of 
QoL on mortality is adjusted for BNP levels, a widely accepted marker for disease 
severity and a prognostic tool to predict mortality. 1 1 ,22 
Previous research showed inconsistent results on physical QoL to be a predictor 
of mortality.3 When looking at the four studies which used a disease-specific QoL 
questionnaire and had a follow-up period >2 years, all studies found a significant 
association between the physical component of their questionnaire and 
mortality.6,7,23,24 However, our results on the physical dimension of the MLwHFQ 
being a predictor for survival independent of BNP levels do not confirm these 
findings. Studies including the physical dimensions of disease-generic QoL 
questionnaires to predict mortality, are not consistent.6,7,25,26 Two studies did find 
physical functioning to be independently associated with mortality7,25 and two 
other studies did not find this association. 6,24 However, these two studies had 
limitations in the generalizability of their results due to their relatively small sample 
size26 and a very specific HF patient sample, namely male veterans.6 Both studies 
which showed consistent findings had a relatively large (n=3375 and n=433) and a 
more generalizable HF patient sample.7,25 
In our study we extend previous studies by taking the research to the next level by 
exploring which patients report low QoL in order to address future interventions 
for improving QoL, and reducing mortality. In our data we found several factors 
related to low QoL that could be used in identifying patients with low QoL, eg, 
higher age, female gender, being diagnosed with HF for longer, and co­
morbidities. Other factors related to low QoL, which can be used to identify 
patients, but which also can be influenced by interventions and therefore possibly 
improve QoL, are high NYHA functional class (III-IV), low eGFRs and no 
prescription of beta-blockers. 
To improve NYHA functional class, it can be suggested to include an exercise 
component in the treatment programmes of HF patients. Several studies have 
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shown that exercise programmes improve QoL.27 Two meta-analyses of exercise­
based rehabilitation clinical trials in patients with HF identified a significant 
benefit of exercise training on all-cause mortality and total cardiac mortality.28,29 
Furthermore, our results show that patients with a low QoL had fewer beta­
blocker prescriptions. The effectiveness of beta-blockers for mortality is well 
tested, 1 and showed a trend towards improvement of QoL in patients receiving 
beta-blocker therapy.30 
The current study underlines the importance of QoL in patients with HF.31 
Previous research on patients' preferences show that patients give equal or more 
importance to QoL when compared with length, and about half of a HF patient 
population is willing to select therapies that improve their QoL, even if this leads 
to shortening of life,32.33 although one study showed the opposite results.34 In the 
past study outcomes focused mainly on reducing hospitalizations and mortality. 
Nowadays, QoL is increasingly incorporated as an outcome measure in clinical 
trials.35-37 Furthermore, in the HF guidelines, improving QoL is recognized as one 
of the major treatment goals. 1 5  Adding our findings that QoL is independently 
associated with mortality, to the relevance of QoL for individual patients, for 
research outcomes and for clinical practice, the value of QoL cannot be ignored. It 
is of great importance to develop and evaluate treatment programmes that 
effectively improve QoL in HF patients. However, there are few randomized 
studies that specifically focus on improving QoL in patients with HF. Some 
studies on disease management programmes have shown improvement in QoL as 
a result; unfortunately, the findings are inconsistent.JS 
It might be debated that the concepts QoL and depression are overlapping. 
Quality of life is defined by the World Health Organization as 'an individual's 
perception of their position in life in the context of the culture and value systems 
in which they live and 1n relation to their goals, expectations, standards and 
concerns'.39 Depression 1s defined by the DSM-IV (Diagnostic and Statistic! 
Manual of Mental Disorders, Fourth Edition) as a mental disorder that presents 
with depressed mood, loss of interest or pleasure, weight loss, feelings of guilt or 
low self-worth, disturbed sleep or appetite, fatigue and poor concentration, and 
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can be classified under the heading of the psychological function of the QoL 
domains.4° From our COACH database, we previously published data that showed 
that 39% of patients with HF had depressive symptoms (Center for 
Epidemiological Studies Depression scale (CES-D) score >16) and having severe 
depressive symptoms was significantly associated with death and readmission 
within 18 months of follow-up after a hospital admission.41 In the current study 
we did not include depressive symptoms measured by the CES-D, but did include 
several mental health and emotional dimensions of the different QoL 
questionnaires. These dimensions include fewer items than the CES-D, and are 
not specifically focused on depression, but more on emotions and mental health in 
general. 
The present study is limited, in that the follow-up period for mortality was 3 years 
which is relatively short compared with other studies on QoL being a predictor for 
long-term mortality which have used follow-up periods of 5-7 years.6,7 However, 
our sample size was relatively large (n=661) compared with the previous studies 
on long-term mortality, which had sample sizes of respectively 416 and 459 HF 
patients, respectively. Furthermore, our mortality rate was 42% and which is 
comparable with the mortality rates of both the other long-term follow-up studies 
(eg, 44% and 70%) and therefore high enough for reliable analyses on comparing 
QoL between survivors and non-survivors. A second limitation is generalizability 
of the study cohort. Only hospitalized patients with HF were included, which is 
only part of the total HF patient population. 
In conclusion, the present study is the first study on QoL and long-term mortality 
in HF in which BNP levels were used as an objective marker to reflect the severity 
of HF. Our results show that QoL assessed during a hospitalization for HF is a 
predictor for 3-year mortality independent of BNP levels and a wide range of 
demographical and clinical variables. In particular general health and physical 
functioning assessed with a disease-generic QoL questionnaire provide prognostic 
information on survival in addition to other prognostic variables. Patients with low 
scores on these dimensions were more likely to be in NYHA III-IV, diagnosed 
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with comorbidities, suffered from HF for longer, had lower eGFRs, and had fewer 
beta-blocker prescriptions. 
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Abstract 
Aims: To compare quality of life (QoL) in heart failure(HF) patients with 
preserved ejection fraction (HF-PEF) and HF patients with reduced ejection 
fraction (HF-REF) in a well-defined HF population. 
Methods and results: Patients with HF-PEF (left ventricular ejection fraction 
(LVEF) :::=:40%) were matched by age and gender to patients with HF-REF (LVEF 
<40%). In the current study, we only included HF patients with a B-type 
natriuretic peptide level (BNP) > 100 pg/ mL. Quality of life was assessed by 
Cantril's Ladder of Life, RAND-36 and the Minnesota Living with Heart Failure 
questionnaire, and impairment of QoL was adjusted for by BNP as a marker for 
severity of HF. 
We examined a total of 290 HF patients, of whom 145 had HF-PEF (41 %  female; 
age 72 ± 10; LVEF 51 ± 8%) and 145 had HF-REF (41 %  female; age 73 ± 1 0, 
LVEF 26 ± 7%). All HF patients reported markedly low scores of QoL, both on 
the general and disease specific QoL questionnaires. Quality of life between 
patients with HF-PEF and HF-REF did not differ significantly. When adjusting 
the QoL scores for BNP, an association between QoL and LVEF was not found, 
i.e. patients with HF-PEF and HF-REF with similar BNP levels, had the same 
impairment in QoL. 
Conclusion: Quality of life is similarly impaired in patients with HF-PEF as in 
HF-REF. These findings further support the need for more pharmacological and 
non-pharmacological studies in patients with HF-PEF. 
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1. Introduction 
Heart failure (HF) has a major impact on the quality of life (QoL) of patients, in 
physical, mental and social domains. 1 ,2 Patients with HF have a significantly lower 
QoL than an age- and gender-matched members of the community.3 But even 
compared to other chronically ill patients, patients with HF have similar or even 
more impaired physical and mental health.4 In recent years, patient-centred 
outcomes, such as QoL, have gained greater importance, particularly because life 
expectancies for HF patients have increased, and HF patients have to adjust to 
living with a chronic condition and for many (elderly) patients QoL appears to be 
more important than longer survival.5,6 In addition, impaired QoL is increasingly 
associated with a poor outcome in HF.7,8 
In HF patients, the large majority of studies have been conducted in patients with 
a reduced ejection fraction (HF-REF). However, at least 50% of all HF patients 
have HF with a preserved ejection fraction (HF-PEF).9,10  Symptoms and signs 
often seem similar in patients with HF-PEP and HF-REF. 1 1  However, no 
treatment has been shown to be effective in HF-PEP patients, and current 
guidelines do not support the use of any class of drugs in this patient category.1 
There is only limited knowledge about the QoL of patients with HF-PEP 
compared with patients with HF-REF. Five studies that compared QoL in these 
two populations showed inconsistent results, reporting either no significant 
differences in QoL' l- 14 or more impaired QoL in patients with HF-REF.15 
Previous reports about the QoL of patients with HF-PEP were not only relatively 
small, but they also used the New York Heart Association (NYHA) functional 
class to adjust for severity of HF, which of course affects QoL as well. Indeed, 
none of the aforementioned studies used an objective diagnostic marker for the 
severity (and presence) of HF. Especially in patients with HF-PEP, the diagnosis 
of HF is often more difficult, and in fact some patients with assumed HF-PEP do 
not have HF but suffer from another condition such as anaemia, lung disease, or 
even depression.9,IO  
We therefore studied a large number of QoL measurements in a group of patients 
with HF-PEP, compared to a matched group of patients with HF-REF. In order 
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to try to obtain an objective parameter for the severity of HF, we used plasma 
levels of B-type natriuretic peptide (BNP), since this is an independent and reliable 
marker of HF severity.16 
2. Methods 
2.1 Patient population 
Data from patients participating in the COACH (Coordinating study evaluating 
Advising and Counselling in Heart failure) study were used. COACH was a 
multicenter, randomized clinical trial on the effect of a disease management 
programme in HF, the design and main results have been published.1
7,1 8  In short, 
1023 patients from 17 hospitals in The Netherlands were enrolled in the COACH 
study. Patients were included in the study at the end of hospitalization for HF 
(NYHA functional class II to IV), with HF as the primary diagnosis. The 
diagnosis was based on a combination of typical signs and symptoms according to 
the European Society of Cardiology guidelines 1 for which a hospital stay was 
considered necessary, and the need for intravenously administered medication. 
During hospitalization all patients received standard care, both pharmacological 
and non-pharmacological, according to the guidelines 1 in a cardiology ward, 
staffed by cardiologists and registered nurses. Patients were 18 years or older and 
had evidence of structural underlying heart disease as shown at cardiovascular 
imaging. Exclusion criteria were: concurrent inclusion in a study requiring 
additional visits to research health care personnel; restric tions that made the 
patient unable to fill in data collection forms; invasive intervention within the last 
6 months or planned during the following 3 months; or ongoing evaluation for 
heart transplantation. All patients gave written informed consent. Although all 
patients in the COACH study had HF as the primary diagnosis and were included 
in experienced HF centres, in the current analyses we only included patients who 
had a BNP plasma level > 100 pg/mL, to strengthen the evidence for a diagnosis 
of HF in all patients. 1 ,19 
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The study was performed in accordance with the principles outlined in the 
Declaration of Helsinki and was approved by the Medical Ethics Committee in 
each participating centre. 
2.2 Data collection 
2.2.1 Left ventricular ejection fraction and brain natriuretic peptide 
Data on left ventricular function (L V function) were obtained by standard trans­
thoracic echocardiography. These data were used to distinguish between HF-PEF 
and HF-REF. Reduced LV systolic function was defined as an LVEF <40% (HF­
REF); and preserved LV systolic function was defined as an L VEF 2::40% (HF­
PEF). In the current analyses, only patients with complete echocardiographic data 
were included. Plasma BNP levels were determined within 4h of blood collection 
(1 mL blood, collected in EDTA), on the day of hospital discharge or on the day 
before hospital discharge. All BNP measurements were performed using a 
fluorescence immunoassay kit (Triage®; Biosite Incorporated, San Diego, CA, 
USA). 1 9  
2.2.2 Quality of life 
Data on QoL in the COACH study were collected during the index hospitalization 
and during follow-up. To minimise the confounding effect of the recent 
hospitalization on QoL, we used QoL data collected one month after discharge. 
Quality of life was assessed in three different ways: global well-being, general QoL 
and disease specific QoL. 
Global well-being was assessed by Cantril's Ladder of Life. This is a single-item 
measure which asks the patient to rate their sense of well being on a ladder, with 
10 reflecting the best possible life imaginable and O reflecting the worst possible 
life imaginable. A higher score indicates better well being.20 
General QoL was assessed by the Medical Outcome Study 36-item General Health 
Survey (RAND-36), a self-report questionnaire of general health status. It is a well­
validated generic, 36-item questionnaire that includes 9 health concepts that 
represent dimensions of QoL: physical functioning, social functioning, role 
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limitations because of physical functioning, role limitations because of emotional 
functioning, mental health, vitality, bodily pain, general health and perceived 
health change. Each dimension has a score between O and 100; a higher score 
means better health.21 
Disease specific QoL was measured with the Minnesota Living with Heart Failure 
(lvILwHF) questionnaire.22 The MLwHF questionnaire is a 21 -item questionnaire 
assessing how HF has affected the life of the respondent during the last month. 
The MLwHF has a scoring range of zero for no impairment as a result of HF to 
105 for maximum impairment. The questions cover symptoms and signs relevant 
to HF, physical activity, social interaction, sexual activity, work and emotions. 
Three scores can be determined: an overall score (21 items, 0-1 05), the physical 
dimension (8 items, 0-40) and the emotional dimension (5 items, 0-25). Higher 
MLwHF scores mean a worse QoL. 
2.3 Statistical analysis 
The two patient groups (HF-PEF and HF-REF) were matched by age (10 year 
categories) and gender to have a fair test of differences.23 First, descriptive 
statistics were used to characterize the HF-PEF and HF-REF patients. For 
continuous variables means and standard deviations and for categorical variables 
frequencies with percentages were used. Secondly, differences on QoL between 
both HF patient groups were univariately tested using the Mann-Whitney U test. 
Thirdly, a Spearman correlation was calculated between BNP and QoL in the total 
group to analyze the relation between QoL and BNP levels. Finally, to adjust for 
an objective measure of the severity of HF, an Analysis of Covariance 
(ANCOVA) was performed using QoL scores as the dependent variable and BNP 
as the covariate. The more subjective measure for the severity of HF, NYHA 
functional class, was not included in the analysis because of an overlap with 
(physical dimensions of) QoL. 
Analyses were performed using SPSS for windows version 1 6  (SPSS Inc., Chicago, 
USA). Outcomes were considered statistically significant when p<0.05. 
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3. Results 
3.1 Patients 
Of the 1023 patients included in the main COACH study, an L VEF measurement 
and a BNP level was available in 698 patients. Of these, 627 patients had a BNP 
level > 100 pg/ mL. Within this patient sample, QoL questionnaires at one month 
after discharge were completed by 485 patients. Only patients who completed all 
questionnaires were included in the current study. Of these, 31 % had an L VEF 
�40% and 69% had an LVEF <40%. 
After matching for age and gender, both patient groups consisted of 145 patients. 
Due to the process of matching, 195 HF patients (1 90 LVEF <40%, 5 LVEF 
�40%) were not analyzed. These excluded HF patients were younger, more often 
male, had a lower mean L VEF, and their QoL was slightly better on physical 
functioning of the MLwHF questionnaire. (p<0.05). All other domains of QoL, 
and the BNP levels were similar in both groups. 
3.2 Characteristics 
Patients with HF-PEF were on average 72 (± 10) years old, 41% were female and 
the mean LVEF was 50% (± 8%). Patients with HF-REF were on average 72 (± 
10) years old, 41 % were female and the mean LVEF was 26% (± 7%) (Table 1 ). In 
patients with HF-PEP the prevalence of hypertension was higher than in patients 
with HF-REF (p=0.025). Brain natriuretic peptide levels were significantly higher 
in the HF-REF patient group (p=0.001 ). More patients with HF-REF were 
classified as NYHA functional class III-IV at discharge than patients with HF­
PEF (p<0.001) (Table 1 ) .  
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Table 1: Demographic and clinical characteristics of the matched patient 
groups at discharge 
HF-REF HF-PEF p-value (n=145) (n=145) 
Demographics 
Age (years) 72 ± 10  72 ± 10  .739 
Female 41% 41% 1.000 
Clinical characteristics 
LVEF % 26 ± 7 so ± 8 <.001 
NYHA III-IV 61% 38% <.001 
BNP (pg/mL) median (IQR) 516 (290-1125) 370 (21 5-755) .001 
Hypertension 37% 50% .025 
lschaemic heart failure 43% 43% .946 
Myocardial infarction 46% 37% .095 
Duration of heart failure (years) 2.7 ± 4.3 2.7 ± 4.5 .853 
Medication 
ACE-inhibitors/ ARB 88% 81% .102 
Beta-blockers 67% 66% .901 
Diuretics 97% 97% 1 .000 
Co111orbidities 
COPD 22% 30% . 109 
Diabetes 30% 28% .699 
Stroke 10% 7% .394 
Abbreviations: LVEF=left ventricular ejection fraction; NYHA=New York Heart 
Association; BNP=B-type Natriuretic peptide; IQR=lnter Quartile Range; 
ACE=Angiotensin Converting Enzyme; ARB=Angiotensin Receptor Blocker; 
COPD=Chronic Obstructive Pulmonary Disease 
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3.3 Quality of Life 
Global wellbeing, as measured with Cantril's Ladder of Life, did not differ 
significantly between patients with HF-PEF and HF-REF (6.3 vs. 6.3, p=0.862). 
Scores of all dimensions of the RAND-36 varied between 17 and 78, on the 
theoretical range between 0-100, with the lowest scores for role limitations 
physical, physical functioning and health change. None of the dimensions of the 
general QoL, measured with RAND-36, differ significantly between HP-REF and 
HF-REF patients, except for bodily pain (HF-PEF vs. HF-REF, 70 vs. 78, 
p=0.006). 
The mean score on the total scale of the MLwHF questionnaire was 41. On the 
physical and emotional subscales, mean scores were 21 and 8, respectively. Also 
on the MLwHF questionnaire, patients with HF-PEF did not rate their QoL 
different than patients with HF-REF. The total scores as well as the scores on the 
physical and emotional functioning subscales did not differ significantly between 
both groups (Table 2). 
3.4 Relationship between brain natriuretic peptide and quality of life 
Global wellbeing was not significantly related to BNP levels in the total patient 
group (n=290). Of the dimensions of the RAND-36, health change was 
significantly correlated to BNP levels (rho=.124, p<0.05). All other dimensions of 
the RAND-36 were not significantly correlated to BNP levels. Disease specific 
QoL, as measured with the :MLwHF questionnaire, was significantly correlated 
with BNP levels. There was a correlation with the total score (rho=.132, p<0.05) 
and the physical subscale of the MLwHF questionnaire (rho=.151, p<0.01). There 
was no significant correlation between BNP levels and the emotional subscale of 
the MLwHF questionnaire. 
Table 2. Quality of life in heart failure patients with reduced (HF-REF) and preserved left ventricular 
ejection fraction (HF-PEF) 
Total (n=290) HF-REF (n= 1 45) HF-PEF (n= 145) p-value* Baseline 1 month Baseline 1 month Baseline 1 month 
Ladder of Life 
Well-being 6.3 ± 2 6.3 ± 2 6.5 ± 2 6.3 ± 2 6.2 ± 2 6.3 ± 1 .866 
RAND-36 
Physical functioning 34 ± 27 40 ± 28 32 ± 27 38 ± 27 35 ± 27 43 ± 28 . 165 
Social functioning 53 ± 32 57 ± 29 51 ± 33 55 ± 31 55 ± 31 59 ± 27 .296 
Role limitations Physical 1 8  ± 33 20 ± 34 1 9  ± 33 17 ± 33 17 ± 33 22 ± 35 .1 56 
Role limitations Emotional 51  ± 45 48 ± 46 53 ± 46 48 ± 46 50 ± 46 49 ± 46 .807 
Mental Health 67 ± 23 70 ± 21 67 ± 24 69 ± 21 66 ± 21 70 ± 20 .908 
Vitality 41 ± 23 49 ± 23 42 ± 25 48 ± 23 39 ± 22 49 ± 23 .938 
Bodily Pain 63 ± 33 74 ± 28 66 ± 32 78 ± 26 61 ± 33 70 ± 28 .006 
General Health 44 ± 1 8  45 ± 1 9  44 ± 1 7  45 ± 1 9  44 ± 19  45 ± 1 9  .956 
Health Change 26 ± 23 34 ± 29 25 ± 23 34 ± 29 27 ± 23 34 ± 29 .817 
Minnesota Living 1vith Heart Failure 
Total 45 ± 21 41 ± 22 46 ± 21 41 ± 23 44 ± 21 41 ± 21 .816 
Physical functioning 24 ± 1 0  21  ± 1 1  25 ± 1 0  2 1  ± 1 1  24 ± 1 1  20 ± 1 1  .704 
Emotional functioning 7 ± 6  8 ± 6  7 ± 6  8 ± 6  7 ± 6  8 ± 6  .692 
* Comparison between HF-REF and HF-PEF patient groups at 1 month after discharge 
Quality of life is impaired similarly in patients with HF-PEF and HF-REF 1 59 
3.5 Adjustment for brain natriuretic peptide 
After adjusting the QoL scores for BNP level, QoL was not associated with 
L VEF. There were no differences in the adjusted global wellbeing scores between 
patients with HF-PEF and HF-REF (6.3 vs. 6.3, p=0.671) (Figure 1). The adjusted 
general QoL did not differ between the two groups, except for the bodily pain 
dimension, in which patients with HF-PEF had a significantly lower score, which 
means worse QoL (70 vs. 77, p=0.020) (Figure 1) compared with the HF-REF. 
The scores on the disease specific QoL questionnaire (MLwHF) did not differ on 
the total score or on both subscales (physical and emotional functioning) between 
the two groups (Figure 1) . 
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Figure 1. Quality of life in patients with HF-REF and HF-PEF, 
multivariate tested and adjusted for brain natriuretic peptide. * p<0.05. 
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4. Discussion 
The main finding of the present study is that QoL in patients with HF-PEF is as 
severely affected as it is in patients with HF-REF. This similarity between HF­
PEP and HF-REF patients is consistent on several domains of QoL, both disease 
generic and disease specific. When we adjusted the QoL scores for BNP, as a 
marker for the severity of the disease, an association between QoL and L VEF was 
not found, despite the significant correlation between BNP and several QoL 
domains (health change of the RAND-36, physical and total scores of the 
MLwHF questionnaire) i.e. patients with HF-PEP and HF-REF with similar BNP 
levels, had the same impairment in QoL. 
Although the two patient groups differed significantly in terms of the number of 
patients in NYHA III-IV at discharge, and a linear association between NYHA 
and (physical) QoL could be suggested, we did not find significant differences in 
QoL scores. This might be due to the fact that QoL includes more dimensions 
than physical function alone as measured by NYHA functional class. Although 
NYHA functional class definitely influences QoL, eg, the scores between both 
groups differed the most for the physical function dimensions, the QoL scores 
between the two groups did not differ significantly. 
It is well-known known that QoL is affected by gender and age and patients with 
HF-PEP and HF-REF are different regarding these two variables. Patients with 
HF-PEP are more often female and older9, 1 0  and in general it would seem that 
QoL is lower in patients with HF-PEP. By using the matching technique (on age 
and gender23) we showed, however, that possible differences in QoL are not due 
to differences in L VEF but probably caused by the presence of more patients with 
higher age and female sex in the HF-PEP group compared to the HF-REF group. 
To our knowledge this is the first study to compare QoL between HF-PEP and 
HF-REF patients that has used an independent and reliable marker for the severity 
of HF (i.e. BNP). Although the diagnosis of HF in the COACH study was already 
well defined, in the current study we only included patients with plasma BNP 
levels >100 pg/mL. In previous studies, HF patients were defined using more 
subjective criteria such as NYHA class or an admission to the hospital with a 
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cardiovascular problem in the previous 6 months, 1 3 an admission to the cardiology 
ward with symptoms of HF, 1 1 the application of the European Study Group 
criteria12 or a clinical score of three or greater from NHANES I (National Health 
and Nutrition Examination Survey I). 14,1 5  There are several possible subjective and 
objective markers of disease severity in HF, for example NYHA functional class, 
sodium restriction, and renal dysfunction. We chose to use BNP levels as a marker 
for disease severity in our analysis, because this is an objective and a generally 
accepted measure for the severity of HF,1 and has no direct overlap with (physical 
dimensions of) QoL like NYHA functional class. 
There are almost no studies published on the comparison of QoL between HF­
PEF and HF-REF. One of the few studies that have been published is by Lewis et 
al. 1 3  from the large CHARM population (n=2709), who reported that QoL was 
associated with LVEF and was equally impaired in HF-PEF and HF-REF. Our 
results further extend the findings of this previous study in several respects. First, 
our study had the advantage of using an objective marker for the presence of HF 
(LVEF combined with elevated BNP levels in both the HF-PEF and HF-REF 
groups), making us more confident that the patients with HF-PEF had HF and 
were not suffering from different diagnoses. Secondly, our study extends previous 
observations by using multiple QoL assessments to demonstrate the similarity in 
different domains of QoL, such as general well being, physical and social 
functioning, role limitations and disease specific QoL between the two groups. 
Thirdly, we deliberately chose to match the two patient groups instead of putting 
age and gender into the multivariate model to have a fair test of comparison. In 
QoL research between groups of patients, statistical analyses often ignore the 
meaning of differences in age and gender. When age and gender are treated as 
nuisance variables and are dealt with by statistical control, we are actually forming 
a counterfactual situation. In this sense 'controlling for age and gender' 
substantively means attempting to eliminate the effects of significant differences in 
role responsibilities.23 Quality of life is experienced differently by men and women, 
and by younger and older patients, therefore we decided to match the two patient 
groups instead of controlling for age. 
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While patients with HF-PEP appear to have similar symptoms of HF and their 
prognosis is as poor as those with HF-REF9, 1 0,24 no treatment option has been 
proven effective in this population. Although, favourable effects on clinical 
endpoints (hospitalizations and mortality) have been suggested in some (sub-) 
populations of patients with HF PEP for angiotensin converting enzyme (ACE) 
inhibitors,25 angiotensin receptor blockers,26 and beta-blockers,27 none of these 
agents has shown a significant benefit on outcome in large randomized studies, 
and none of them has therefore received a recommendation in current guidelines.1 
When it comes to QoL, few studies have focused specifically on the HF-PEP 
population. Nevertheless, it appears that QoL is gaining increasing attention in 
HF-PEP, and in one recently reported study with valsartan28 and in another 
ongoing study with spironolactone,29 QoL is one of the important endpoints. 
There are a few limitations to the present study. First, due to the process of 
matching 195 patients, mostly patients with HF-REF, were excluded from the 
analysis. However, we deliberately chose to match the two patient groups instead 
of including age and gender in the multivariate analysis to have a fair test of 
comparison, and gain a more representative clinical insight in the comparison of 
QoL between patients with HF-PEP and HF-REF.23 Secondly, we defined HF­
PEP as an LVEF 2:40%. At present the cut-off point of LVEF to diagnose HF­
REF or HF-PEP is still a matter of debate, we chose a cut-off of 40% because it 
has been used in other large databases, 13 and because otherwise very few patients 
would have been included in the HF PEP group. Thirdly, in the current study we 
used QoL data at one month after discharge, while BNP levels were collected at 
discharge. We deliberately chose to use the QoL data at one month after discharge 
to minimise the confounding effect of the recent hospitalization. 
In conclusion, patients with symptomatic HF with preserved LVEF (HF-PEP) 
and elevated levels of BNP suffer from their HF as much as age- and gender­
matched HF patients with HF-REF, resulting in a comparably low QoL and well­
being. Pharmacological and non-pharmacological management interventions that 
have proved to be successful in HF-REF patients to improve QoL, might be 
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successful in HF-PEF too. Further research to test whether these interventions 
can improve QoL is now needed. 
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Abstract 
Aims: The diagnosis of heart failure with a preserved ejection fraction (HF-PEF) 
is often difficult. Natriuretic peptides such as B-type Natriuretic Peptide (BNP) 
may possibly be used in the diagnosis. Current guidelines use a cut-off level for 
BNP of >l00pg/ml in order to confirm the diagnosis of HF. All patients included 
in the COACH study were assumed to have HF, based on HF symptoms. To 
examine whether HF-PEF patients with BNP-levels<lO0pg/ml differ from HF­
PEP patients who have BNP-levels>l00pg/ml, we compared clinical 
characteristics, HF symptoms and quality of life (QoL) measurements in a group 
of HF-PEF patients who were enrolled in COACH. 
Methods: Thirty-seven patients with BNP-levels<l00pg/ml and left ventricular 
ejection fraction (LVEF)>40% (54% male, age 72 years) were compared with 162 
patients with BNP-levels>lO0pg/ml and LVEF>40% (57% male, age 73 years). 
Data on BNP-levels, QoL, demographic and clinical variables were assessed at 
discharge for a hospital admission for HF. 
Results: Patients with low BNP-levels were more often in NYHA III-IV (60% vs. 
38%, p=0.016), more often obese (47% vs. 24%, p=0.007), and had a higher mean 
L VEF (54% vs. 50%, p=0.003) than patients with high BNP-levels. Both patient 
groups did not differ on other comorbidities like anaemia, COPD, diabetes and 
hypertension. Quality of life between patients with low and high BNP-levels did 
not differ significantly, although there was a clinical relevant difference in QoL in 
which patients with low BNP-levels had worse physical functioning, general health 
and bodily pain. Of all the HF-symptoms, only loss of appetite differed 
significantly between both groups, and was less often reported by patients with 
high BNP-levels (33% vs. 52%, p=0.044). 
Conclusion: Patients with a preserved ejection fraction and BNP­
levels<100pg/ml do not differ on a broad range of characteristics, comorbidities, 
HF symptoms and QoL parameters from patients with BNP-levels>lO0pg/ml, 
except for obesity. 
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1. Introduction 
There is an increasing interest in patients with heart failure with preserved ejection 
fraction (HF-PEP). The prevalence of HF-PEP among patients with heart failure 
(HF) is high; at least 50% of all HF patients have HF-PEF. 1 ,2 Symptoms and signs 
often seem similar in patients with HF-PEP and HF-REF, and quality of life 
(QoL) is equally impaired.3,4 In general, patients with HF-PEP are older, more 
often female, more predominantly hypertensive, and have a higher prevalence of 
atrial fibrillation, but a lower prevalence of coronary artery disease compared to 
patients with heart failure and reduced ejection fraction (HF-REF).5 Furthermore, 
the prevalence of comorbidities, like obesity, anaemia, chronic lung disease and 
diabetes mellitus, also appear to be highly prevalent in patients with HF-PEF.5 
Due to the presence of these comorbidities, including symptoms which resemble 
HF symptoms, the diagnosis of HF is often difficult, and in fact some patients 
with assumed HF-PEP do not have HF, but suffer from another condition such 
as anaemia, lung disease, or depression.1 ,2 
Nowadays the guidelines of the European Society of Cardiology state that 
untreated patients with symptoms of HF should at least have plasma levels of B­
type natriuretic peptide (BNP) of 100pg/ ml to confirm the diagnosis of HF. 6,7 The 
inclusion of this criterion in the guidelines may be a first step to diagnose HF-PEP 
easier, and differentiate between patients with HF and patients with other 
conditions. Nevertheless, in clinical practice, determination of plasma levels of 
BNP is still not standardized, and specialists are confronted with many patients 
complaining of severe symptoms of exercise intolerance, breathlessness, and poor 
quality of life despite a 'normal' ejection fraction. These patients are still largely 
ignored, under diagnosed, and under treated. 8 Therefore, there is a need to better 
define, understand and treat HF-PEF.8 
However, due to the inclusion of having a plasma BNP-level>100pg/ml to meet 
the diagnostic criteria of HF or HF-PEP, a group of patients with HF symptoms, 
a preserved ejection fraction and BNP-levels<l 00pg/ml do not meet the HF 
diagnostic criteria anymore. Except for their BNP-levels, there is no knowledge on 
how these patients differ from patients with HF-PEP and BNP-levels>100pg/ml, 
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and how they would be diagnosed and treated now. Therefore, in order to gain 
more insight in the characteristics of patients with a preserved ejection fraction 
and BNP-levels<100pg/ml, we compared patient characteristics, HF symptoms 
and QoL measurements of these patients to patients with HF-PEP and BNP­
levels higher than 1 00pg/ ml. 
2. Methods 
2.1 Patient population 
Data were collected as part of the COACH study (Coordinating study evaluating 
Outcomes of Advising and Counselling in Heart failure). COACH was a 
multicenter, randomized clinical trial on the effect of a disease management 
program in HF, the design and main results have been published.9,10 In short, 1023 
patients from 17 hospitals in the Netherlands were enrolled in the COACH study. 
Patients were included in the study during a hospitalization for HF (NYHA 
functional class II to IV), with HF as the primary diagnosis. The diagnosis was 
based on a combination of typical signs and symptoms according to the ESC 
guidelines 1 1 for which a hospital stay was considered necessary. During 
hospitalization all patients received standard care, both pharmacological and non­
pharmacological, according to the guidelines in a cardiology ward, staffed by 
cardiologists and registered nurses. 1 1 Patients were 18 years or older and had 
evidence of structural underlying heart disease. Exclusion criteria were: concurrent 
inclusion in a study requiring additional visits to research health care personnel; 
restrictions that made the patient unable to fill in data collection forms; invasive 
intervention within the last 6 months or planned during the following 3 months; 
or ongoing evaluation for heart transplantation. All patients gave written informed 
consent. 
In the current study only patients with an L VEF �40%, with complete data on 
BNP-levels and all QoL instruments were included. The study was performed in 
accordance with the principles outlined in the Declaration of Helsinki and was 
approved by the Medical Ethics Committee in each participating centre. 
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2.2 Left ventricular ejection fraction and brain natriuretic peptide 
Data on left ventricular function (L V function) were obtained by standard trans­
thoracic echocardiography. These data were used to define HF-PEP as having an 
L VEF :2'.40%. Plasma BNP levels were determined within 4h of blood collection 
(1ml blood, collected in EDTA), on the day of hospital discharge or on the day 
before hospital discharge. All BNP measurements were performed using a 
fluorescence immunoassay kit (Triage®; Biosite Incorporated, San Diego, CA, 
USA). 1 2  
2.3 Quality of life 
Data on QoL were collected during hospitalization. Quality of life was assessed in 
three different ways: global well-being, disease generic QoL and disease specific 
QoL. 
Global well-being was assessed by Cantril's Ladder of Life. This is a single-item 
measure which asks the patient to rate their sense of well being on a ladder, with 
10 reflecting the best possible life imaginable and O reflecting the worst possible 
life imaginable. Cantril's Ladder of Life has been used in various cardiovascular 
studies and is considered to be a valid measure of global well-being. 13 A higher 
score indicates better well being. 1 4  
Disease generic QoL was assessed by the Medical Outcome Study 36-item 
General Health Survey (RAND36) , a self-report questionnaire of general health 
status and comparable to the Short-Form-36 Health Survey (SF-36). 1 5,1 6  The 
RAND36 is a well-validated generic, 36-item questionnaire that includes 9 health 
concepts that represent dimensions of QoL: physical functioning, social 
functioning, role limitations because of physical functioning, role limitations 
because of emotional functioning, mental health, vitality, bodily pain, general 
health and perceived health change. Each dimension has a score between O and 
100; a higher score means better health. 1 5  
Disease specific QoL was measured with the Minnesota Living with Heart Failure 
questionnaire (MLwHFQ). 17 The MLwHFQ is a 21-item scale assessing how and 
to what extent HF has affected the life of the respondent during the last month. 
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The MLwHFQ has a scoring range of zero for no impairment to 105 for 
maximum impairment as a result of HF. The questions cover symptoms and signs 
relevant to HF, e.g. physical activity, social interaction, sexual activity, work and 
emotions. Three scores can be determined: an overall score (21 items, 0-105), the 
physical dimension (8 items, 0-40) and the emotional dimension (5 items, 0-25). 
Higher MLwHFQ scores mean a worse QoL. 
Symptoms of HF were assessed from an interview compnsmg ten structured 
questions. During this interview, patients were asked whether they had 
experienced the following symptoms during the last month: ankle oedema during 
the day, ankle oedema when getting out of bed in the morning, sleep disturbance, 
fatigue, breathlessness at rest and during exertion, orthopnoea, coughing, dry 
cough or loss of appetite. These ten symptoms were clustered in six symptom 
indexes: oedema, sleep disturbance, fatigue, dyspnoea, coughing and loss of 
appetite. A total HF symptom score was obtained from the sum of the six 
symptom indexes. 1 B 
2.4 Statistical analyses 
Descriptive statistics were used to characterize the study population. Data are 
presented as means ± standard deviations or percents. Student's t-tests and Mann 
Whitney tests for continuous variables and Chi square tests for categorical 
variables were performed to compare demographic characteristics, clinical 
characteristics, QoL and HF symptoms between patients with low BNP-levels 
(BNP<100pg/ml) and high BNP-levels (BNP>100 pg/ml). 
Analyses were performed using P ASW Statistics for windows version 18 (SPSS 
Inc., Chicago, USA). Outcomes were considered statistically significant when 
p<0.05. 
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3. Results 
3.1 Patient characteristics 
Of the 1023 patients included in the main COACH study, 199 patients had an 
L VEF �40% and complete data on BNP-levels and all QoL instruments. Patients 
had a mean age of 73 (± 10), 54% was male, had a mean LVEF of 51% (± 9%) 
and the median of the BNP-levels was 305pg/ml (Inter Quartile Range (IQR) 132-
763pg/ml). Of the 199 patients with an LVEF �40%, 37 had BNP-levels lower 
than 100pg/ml (19%). Significantly more patients with low BNP-levels were 
classified as NYHA functional class III-IV than patients with high BNP-levels 
(60% vs. 38%, p =0.016). Patients with low BNP-levels were more often obese 
(47% vs. 24%, p=0.007), were less often treated with beta-blockers and diuretics 
(resp. 35% vs. 65%, p=0.001 and 87% vs. 98%, p=0.001), and had a higher mean 
L VEF (54% vs. 50%, p=0.003) than patients with high BNP-levels (fable 1 ). They 
did not differ from the patients with high BNP-levels on co-morbidities like 
COPD, diabetes and anaemia. 
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Table 1. Characteristics of patients with LVEF >40% 
All patients BNP<l00 BNP>l 00 pg/ml pg/ml p-value* (n= 199) (n=37) (n=162) 
Age 73 ± 10 72 ± 9 73 ± 10 .548 
Gender (male) 54% 54% 57% .762 
NYHA III/IV 42% 60% 38% .016 
LVEF % 51 ± 9 54 ± 10 50 ± 8 .003 
BNP (pg/ mL) median 305 51 (28-73) 433 <.001 (IQR) (132-763) (227-836) 
Heart rate (bpm) 72 ± 13 73 ± 12 72 ± 13 .835 
Systolic blood pressure 1 25 ± 23 127 ± 23 124 ± 23 .533 (mmHg) 
Diastolic blood pressure 69 ± 12 73 _ 14 68 ± 12 .050 (mmHg) 
Ischemic heart failure 59% 65% 57% .406 
Haemoglobin (mmol/L) 8.3 ± 1.3 8.5 ± 1.2 8.3 ± 1.2 .404 
Co-morbidities 
Anaemia** 32% 24% 34% .258 
COPD 32% 35% 32% .668 
Asthma 4% 5% 4% .634 
Obese (BMI>30 kg/m2) 29% 47% 24% .007 
Diabetes 31% 32% 30% .795 
Hypertension 49% 60% 50% .168 
Atrial fibrillation 51% 49% 52% .725 
Medication 
ACE/ARB 79% 81% 78% .718 
Beta-blockers 60% 35% 65% .001 
Diuretics 96% 87% 98% .001 
* Comparison between patients with BNP<l00 pg/ml and BNP>l00 pg/ml 
** Diagnosis anaemia: females Hb<7.5 mmol/1, males Hb<8.1 mmol/1 
Abbreviations: LVEF=left ventricular ejection fraction; BNP=B-type Natriuretic 
peptide; IQR=Inter Quartile Range; NYHA=New York Heart Association; 
COPD=Chronic Obstructive Pulmonary Disease; ACE=Angiotensin Converting 
Enzyme; ARB=Angiotensin Receptor Blocker; 
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3.2 Symptoms of heart failure 
Patients reported on average four symptoms of HF. Most reported symptoms of 
HF were dyspnoea (97%) and fatigue (88%). More than two third of the patients 
had oedema (67%) and sleep disturbance (68%). Sixty-two percent reported 
coughing and 49% loss of appetite. Patients with low BNP-levels did not differ on 
reported symptoms from patients with high BNP-levels, except for loss of 
appetite, which was less often reported by patients with low BNP-levels (33% vs. 
52%) (Table 2). 
3.3 Quality of life 
The mean score on global wellbeing, as measured with Cantril's Ladder of Life, in 
the total group was 6.2, and did not differ significantly between HF-PEF patients 
with low BNP-levels and high BNP-levels (Table 2). 
Mean scores of all dimensions of the RAND36 in the total group varied between 
18 and 67 on the theoretical range between 0-100, with the lowest scores for role 
limitations physical (18 ± 33), health change (26 ± 23) and physical functioning 
(33 ± 26), and highest scores on mental health (67 ± 21) and bodily pain (63 ± 
34). There were no significant differences on the QoL dimensions of the 
RAND36 between patients with low and high BNP-levels (Table 2). However, 
there was a clinical relevant difference (mean scores differed more than 5 points) 1 9  
in on the physical functioning, general health and bodily pain dimensions of the 
RAND36, in which patients with low BNP-levels had worse QoL compared to 
patients with high BNP-levels. 
The mean score of all patients on the total scale of the MLwHFQ was 44. On the 
physical and emotional subscales, mean scores were 23 and 6, respectively. The 
MLwHFQ total scores, as well as the physical and emotional subscale scores did 
not differ significantly between patients with low and high BNP-levels (Table 2). 
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Table 2. Quality of life in patients with LVEF >40% 
All patients BNP<100 BNP>100 pg/ml pg/ml p-value* (n= 1 99) (n=37) (n= 1 62) 
Ladder of Life 
Well-being 6.2 ± 1 .8  6.0 ± 2.0 6.2 ± 1 .8  .435 
RAND-36° 
Physical functioning 33 ± 25 27 ± 22 35 ± 26 .082 
Social functioning 57 ± 32 60 ± 31  57 ± 33 .588 
Role limitations 1 8  ± 33 1 8  ± 33 18 ± 34 .984 Physical 
Role limitations 53 ± 46 52 ± 48 53 ± 46 .942 Emotional 
Mental Health 67 ± 21 66 ± 22 67 ± 21 .775 
Vitality 40 ± 22 37 ± 24 40 ± 22 .410 
Bodily Pain 63 ± 34 59 ± 34 64 ± 34 .417 
General Health 44 ± 1 9  39 ± 1 9  45 ± 1 9  .092 
Health Change 26 ± 23 24 ± 22 26 ± 23 .619 
Minnesota Living 1vith 
Heart Failure'' 
Total 42 ± 21 44 ± 21 41 ± 21 .353 
Physical 23 ± 1 1  23 ± 9 23 ± 1 1  .737 
Emotional 6 ± 6  8 ± 7  6 ± 6  .097 
Symptoms 
Oedema 67% 78% 65% . 1 12  
Dyspnoea 97% 100% 96% . 197 
Cough 62% 54% 64% .251 
Sleep disturbance 68% 62% 70% .370 
Loss of appetite 49% 33% 52% .044 
Fatigue 88% 89% 88% .796 
Total number of 4.3 ± 1 .3 4.2 ± 1 .4 4.3 ± 1 .2 .533 symptoms (0-6) 
* Comparison between patients with BNP<100 pg/ml and BNP>100 pg/ml 
a A higher score means better health 
6 A lower score means better health 
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4. Discussion 
The main finding of our study is that a group of patients presenting with HF 
symptoms who would, based on the current guidelines exclusively due to their 
BNP-levels, not be diagnosed with HF, are at least as much suffering from their 
conditions as patients who do meet the diagnostic criteria of HF. These patients 
with a preserved ejection fraction and BNP-levels<100pg/ml, do not differ from 
patients with HF-PEF and BNP-levels>100pg/ml on a broad range of 
characteristics and HF symptoms, except for that they are more often obese and 
in NYHA III-IV. Furthermore, they have a similarly impaired QoL as patients 
with HF-PEF and BNP-levels>100pg/ml, although there is a clinically relevant 
difference19  in the scores resulting in a worse physical functioning, general health, 
and bodily pain in patients with low BNP-levels. 
Heart failure with preserved ejection fraction (HF-PEF) is increasingly recognized 
as a major public health problem. Although, there is growing interest in reporting 
data on HF-PEF, there is limited understanding pathology of HF-PEF. It is even 
uncertain whether HF-PEF is truly HF, or whether symptoms are a result of 
comorbidities that are highly prevalent in the elderly, such as renal dysfunction, 
anaemia, and lung disease.20,21 Another widely discussed issue concerns the 
diagnosis of HF-PEF.2 1 The HF guidelines of 2008 introduced a requirement of 
plasma BNP-levels>100pg/ml for diagnosing HF, in addition to presence of HF 
symptoms.6,7 Resulting in that patients with HF symptoms but with BNP­
levels<100pg/ ml do not have HF, but actually suffer from another condition. 
Therefore, it is expected that the prevalence of comorbidities among this patient 
population would be higher than in patient with high BNP-levels. However, there 
are no studies on differences in characteristics from the patients with higher BNP­
levels, and their possible diagnose. Our results show no differences between both 
patient groups in comorbidities, except for obesity. It is known that plasma BNP­
levels decrease in obese patients,22,23 which might suggest that these patients still 
suffer from HF-PEF, despite their lower plasma BNP-levels. Furthermore, they 
do not differ in the reported HF symptoms, except for loss of appetite, which is 
less often reported in patients with low BNP-levels, but could be explained by the 
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high number of obese patients in the sample. We did find that these patients are 
worse off when it comes to NYHA functional class. They are significantly more 
often in NYHA III-IV than patients with high BNP-levels, which means they have 
a lower endurance and are faster short of breath. Although, these patients, based 
on the current guidelines, would not be diagnosed with HF, they are at least as 
much suffering from their conditions as patients who would be diagnosed with 
HF. However, the diagnosis of these patients remains unclear, resulting in a 
dilemma for the clinical practice when it comes to who should treat these patients. 
Like patients with HF-PEP, their physical functioning is low, and regardless of 
possible pharmacological treatment, these patients could definitely benefit from 
exercise treatment, and referral to a rehabilitation centre would be advised.24,25 
The findings of the current study raise important questions regarding the use of 
plasma BNP-levels as a biomarker for the diagnoses of HF-PEP. Yamamoto et al 
already stated that we should be cautious in using BNP alone to diagnose HF­
PEF, because concentrations of BNP increase in normal older and/ or female 
individuals, and in those with renal dysfunction and atrial fibrillation, and 
decreases in obese subjects.26 Due to individual changes in plasma BNP-levels it 
could be suggested to measure BNP-levels serially and use changes in BNP-levels 
over time, in stead of a single measurement, to diagnose HF-PEF.27 Although 
BNP-levels have a powerful prognostic value on mortality and morbidity,28 the 
diagnostic value of this biomarker might be debated. The numerous studies on 
finding new biomarkers for diagnosing HF-PEP seem to confirm this.29 31 
Several limitations of this study should be considered. First, the sample size was 
small. However, in the current literature data on differences between HF-PEP 
patients with high and low BNP are not available, and regardless the sample size, 
we did find significant differences. This warrants confirmation of our findings in a 
larger population, and probably statistical trends found in our study, might 
become significant in a larger study population. Secondly, we defined HF-PEP as 
an LVEF �40%. Nowadays, the cut off point of LVEF to diagnose HF-REF or 
HF-PEP is still a matter of debate. We chose a cut-off of 40% because it has been 
used in other large studies.32 
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In conclusion, patients with a preserved ejection fraction and plasma BNP­
levels<100 pg/ml have the same characteristics, the same comorbidities, the same 
HF symptoms, and a similarly impaired QoL as patients with a preserved ejection 
fraction and BNP-levels>100pg/ml, except for that they are more often obese, 
which is known to decrease BNP-levels. 
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Abstract 
Background: Sexual dysfunction is a common problem of increasing incidence in 
patients with heart failure (HF). However, there is no knowledge on which 
demographic, clinical and quality of life (QoL) aspects are related to difficulties in 
sexual activity nor on the course of sexual difficulties in patients with HF. 
Methods: Data on sexual difficulties were collected at 1 and 18 months after an 
HF hospitalization (n=792, mean age 69 ± 12; 35% female; mean left ventricular 
ejection fraction 33% ± 14) by the question on sexuality of the Minnesota living 
with HF questionnaire. Demographic and clinical factors were assessed from 
medical records and QoL by Minnesota living with HF questionnaire, Medical 
Outcome Study 36-item General Health Survey, and Ladder of Life. 
Results: In total 48% (n=380) of the patients perceive difficulties in sexual 
activity at 1 month after discharge, and 70% continued to perceive this at 18 
months. Furthermore, 27% of the patients without difficulties at 1 month 
developed them during follow-up. Living with a partner (OR 3.76, 95% CI 2.58-
5.48), younger age (OR 0.96, 95% CI 0.94-0.97)), male gender (OR 3.08, 95% CI 
2.10-4.43), overall wellbeing (OR 1.13, 95% CI 1.00-1.27), and physical (OR 1.06, 
95% CI 1.06-1.08) and emotional QoL (OR 1.07, 95% CI 1.03-1.10) were 
independently associated with perceived difficulties in sexual activity. 
Conclusions: Perceived difficulties in sexual activity are common in patients with 
HF, particularly in younger and male patients and continue over time. Patients 
who perceive difficulties in sexual activity report a significant lower QoL and 
overall wellbeing than those who do not. 
Perceived sexual difficulties and associated factors 1 89 
1. Introduction 
Heart failure (HF) is a significant health problem affecting the quality of life (QoL) 
of patients. 1 Patients with HF suffer from symptoms such as fatigue and shortness 
of breath,2 psychological factors such as depression, 1 -3 and low functional 
capacit:y4,5, and they also need to manage lifestyle changes.6 These factors affect 
not only overall QoL, but also the intimacy needs of a patient with HF.7 
It is often expected that among seriously ill patients sexual activity is not 
important. However, patients with HF consider sexual activity in their current 
condition as an essential aspect of QoL,8 but symptoms of HF do affect the sexual 
relationships of patients with HF.9 At least 50% of all patients with HF report that 
their sexual activity has reduced or completely ceased as a result of their HF. 
Furthermore, half of the patients with HF have problems with sexual activity 
caused by erectile dysfunction or orgasmic problems and sexual dissatisfaction.7- 1 0  
The current HF guidelines recommend counseling on sexual activity with both 
male and female patients and their partners. The given class of recommendation is 
I; however, the level of evidence is C, which indicates that counseling on sexual 
activity is suggested to be very important, but not many studies have focused on 
this subject. 1 1  Two small studies examining predictors of decrease in sexual activity 
in relatively young, and predominantly male patients with HF show that worse 
functional capacity, high New York Heart Association (NYHA) class, the number 
of medications, diabetes, as well as tobacco and alcohol use contribute to a 
decrease of sexual activity.�,12 Furthermore, HF therapy with beta-receptor 
blockers, digoxin and thiazide are known to worsen sexual activity. 13  However, it 
is not known whether these variables are also related to difficulties in sexual 
activity in an older HF population or specifically in women. In addition, studies on 
sexual problems in patients without a partner are lacking. 
Knowledge on the relationship between difficulties with sexuality and QoL is 
based on a few smaller studies in specific HF study populations and shows that 
better sexual function is related to a higher overall wellbeing.9 To appropriately 
address the importance and effects of difficulties in sexual activity in the lives of 
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all patients with HF, including women and elderly, more information is needed on 
the relationship between QoL and sexual problems. 
Although there is a recent growing interest in reporting data on sexual problems 
of patients with HF, current studies have a cross-sectional design without 
providing insight in sexual problems over time. In case of sexual problems that are 
assessed at hospital discharge, clinicians may assume that these will disappear 
spontaneously during recovery. In general there is little follow-up on the course of 
sexual activity during the trajectory of HF. Only one small study reported that 
both at discharge and at 9 months after discharge patients with HF reported 
problems and sexual concerns. However, this study did not report the 
development of new cases or recovered patients during this period of time.9 
To gain more insight in sexual problems in patients with HF, the following 
research questions were formulated to study in a large representative population of 
patients with HF: 
1. Which demographic and clinical variables are related to difficulties in sexual 
activity? 
2. Which QoL aspects are independently related to difficulties in sexual 
activity? 
3. What is the course of difficulties in sexual activity over time? 
2. Methods 
2.1 Patient population 
Data of patients participating in the COACH (Coordinating study evaluating 
Advising and Counselling in Heart failure) study were used. The COACH study is 
a multicenter, randomized clinical trial on the effect of education and counseling 
in HF.14,15 Between November 2002 and February 2005, 1023 patients from 17 
Dutch hospitals were included in the COACH study. Patients were included in the 
study during admission for HF (NYHA functional class II to IV) ,  with HF as the 
primary diagnosis as confirmed by a cardiologist. During hospitalization patients 
were randomized to (1) basic support, (2) intensive support, or (3) control 
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treatment. Patients were 18 years or older and had evidence of structural 
underlying heart disease as shown at cardiovascular imaging. Reasons for exclusion 
were as follows: concurrent inclusion in a study requiring additional visits to health 
care personnel, restrictions that made the patient unable to fill in data collection 
forms, invasive intervention within the last 6 months or planned during the 
following 3 months, or ongoing evaluation for heart transplantation. All patients 
gave written informed consent. Patients completed questionnaires and were 
interviewed by an independent interviewer not involved in care for these patients. 
All patients were treated from hospital discharge until 18 months afterwards 
hospital discharge. 
The study was performed conform the principles outlined in the Declaration of 
Helsinki and was approved by the Committee for Ethics in Medical Investigations. 
2.2 Data collection 
2.2.1 Difficulties with sexual activity 
Data on sexual activity in the COACH study were collected during index 
hospitalization and follow up. To minimize the confounding effect of the recent 
hospitalization on sexual activity, we used the data on sexual activity at 1 month 
after discharge. Sexual activity was assessed by the following question of the 
Minnesota Living with Heart Failure (MLwHF) questionnaire1 6: "Did your heart 
failure prevent you from living as you wanted during the past month by making 
your sexual activities difficult'" Scoring format consists of O (no difficulties in 
sexual activity) and 1 to 5 (very little to very much difficulties). For the "course of 
difficulties in sexual activity", data at 1 and 18 months after discharge were used. 
Four groups were created based on the scores at the 2 different time points: 
continued difficulties (at 1 and 18 months difficulties with sexuality); new onset 
difficulties (no problems at 1 month and problems at 18 months); recovered 
difficulties (problems at 1 month but not at 18 months), and no difficulties (at 1 
and 18 months). Data on sexual activity was also collected at 6 and 12 months 
after discharge. These data were analyzed as well; however results do not differ 
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from the current results at 1 8  months after discharge. For reasons of readability, it 
was decided not to include these results. 
2.2.2 Demographic and clinical characteristics 
Data on demographic and clinical characteristics were collected from chart review, 
interviews and questionnaires. Depressive symptoms were measured with the 
Center for Epidemiological Studies Depression scale (CES-D), a 20-item self 
report questionnaire designed to measure depressive symptoms in the general 
population and has been widely used with the medically ill. A total sum score is 
used (0-60), with higher scores indicating more depressive symptoms. 1 7,1 8  
Functional capacity was measured by the 6-minute walking test (6MW'T) on a 
predefined course. Patients were instructed to walk as many meters as they could 
within 6 minutes. At standardized moments the instructor told the patients the 
amount of time remaining. Patients were allowed to stop or slow down if 
necessary. The 6MWT is a reliable and well validated test for functional capacity in 
patients with HF. 1 9 
2.2.3 Quality of life 
Data on QoL were collected using several questionnaires completed at 1 month 
after discharge. Disease specific QoL was measured with the MLwHF 
questionnaire,16 a 21 -item questionnaire assessing how HF has affected the life of 
the respondent during the last month. The questions cover symptoms and signs 
relevant to HF such as physical activity, social interaction, sexual activity, work and 
emotions. Three scores can be determined: an overall score (21 items, 0-105), the 
physical dimension (8 items, 0-40) and the emotional dimension (5 items, 0-25). 
Higher scores mean worse QoL. The item on sexual functioning is in neither one 
of both dimensions; however it is part of the total score, therefore the total score 
was excluded from the analyses. 
Overall well-being was assessed by Cantril's Ladder of life. This is a single-item 
measure that asks to rate the sense of well-being on a ladder, with 10 reflecting the 
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best possible life imaginable and O reflecting the worst possible life imaginable. A 
higher score indicates better well-being.20 
General QoL was assessed by the Medical Outcome Study 36-item General Health 
Survey (RAND-36), a self-report questionnaire of general health status. It is a well­
validated generic, 36-item questionnaire that includes 9 health concepts that 
represent dimensions of QoL: physical functioning, social functioning, role 
limitations because of physical functioning, role limitations because of emotional 
functioning, mental health, vitality, bodily pain, general health and perceived 
health change. Each dimension has a score between O and 100; a higher score 
means better QoL.21 
2.3 Statistical analysis 
Data are presented as mean ± SD or as percentages unless stated otherwise. 
Univariate analyses were carried out by using Mann-Whitney U for continues or 
Chi2 for categorical variables. Logistic regression analysis was performed to assess 
which demographic and clinical variables were independently associated with 
difficulties in sexual activity. Difficulties in sexual activity was used as the 
dependent variable. Based on univariate differences with p<0.10, the following 
variables were inserted in the regression model, using backward methods: gender, 
age, living with a partner, left ventricular ejection fraction (L VEF), CES-D, 
6MWT, angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker 
(ARB), diuretics, Ladder of life, MLwHF physical and emotional dimensions, and 
the following dimensions of the RAND-36: social functioning, physical role 
limitations, emotional role limitations, mental health, vitality, bodily pain and 
general health. Student's t-tests were carried out to compare the change in the 
independently associated QoL scores (score at 18 months minus score at 1 month 
after discharge) and the number of hospital admissions between new onset 
patients and patients with no difficulties. 
Analyses were performed using SPSS 16 (SPSS Inc., Chicago, USA). Outcomes 
were considered statistically significant when p<0.05. 
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The COACH study was supported by a program grant from the Netherlands 
Heart Foundation (grant 20002003). Additional unrestricted grants for the main 
COACH study were obtained from Biosite Europe, France, Roche Diagnostics, 
The Netherlands and Novartis Pharma BV, The Netherlands. The authors are 
solely responsible for the design and conduct of this study, all study analyses, the 
drafting and editing of the paper and its final contents. 
3. Results 
3.1 Patients 
Of the 1023 patients included in the COACH study, 44 died within 1 month after 
discharge. Of the survivors, 792 (81 %) patients completed the question about 
sexuality of the MLwHF questionnaire at 1 month after discharge (mean age 69 (± 
12); 35% female; mean LVEF 33% (± 14)). The 187 patients who did not 
complete this question were significantly more often female, older, living without a 
partner, in NYHA III to IV at discharge, diagnosed with diabetes, had a higher 
L VEF and walked less far on the 6MWT. Of the 187 patients who survived the 
follow-up at 1 month after discharge, but specifically did not complete the 
question on sexual difficulty, 51 patients did fill out the rest of the :rv!LwHF 
questionnaire. 
At 18 months after discharge, 638 (81 %) of the 792 patients were alive and 555 
(87%) patients completed the question on sexual activity both at 1 and 18 months 
after discharge. 
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ACE/ ARB ( discharge) 83% 88% .019 
Betablockers (discharge) 66% 71 % .147 
Diuretics (discharge) 94% 97% .072 
Abbreviations: NYHA=New York Heart Association; LVEF=Left Ventricular 
Ejection Fraction; COPD=Chronic Obstructive Pulmonary Disease; BNP=B-type 
Natriuretic peptide; IQR=lnter Quartile Range; BMI=Body Mass Index; CES-D= 
Center for Epidemiological Studies Depression Scale; ACE=Angiotensin 
Converting Enzyme; ARB=Angiotensin Receptor Blocker 
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3.2 Difficulties with sexual activity 
Of the 792 patients, 380 (48%) reported difficulties in sexual activity at one month 
after discharge. Almost half of these patients (n=186) reported considerable 
difficulties, they reported that HF prevented them very much of living as they 
wanted by making their sexual activities difficult. 
Patients with HF who perceive sexual difficulties were more often male (76% vs. 
54%, p<0.001), younger of age (66 vs. 72 years old, p<0.001) and more often 
living with a partner (82% vs. 49%, p<0.001 ), had a lower L VEF (32% vs. 35%, 
p=0.007), had a higher score on a depression scale (16 vs. 15, p=0.035) and 
walked further on the 6MWT (272m vs. 244m, p=0.013) (Table 1). At hospital 
discharge more patients reporting sexual difficulties had a prescription of 
ACE/ ARB (88% vs. 83%, p=0.019). No differences were found regarding beta­
blocker use and the assigned COACH intervention. 
Patients with sexual difficulties had significant lower QoL compared to patients 
without sexual difficulties on both the physical and emotional dimensions of the 
MLwHF questionnaire (23 vs. 17 and 9 vs. 6, p<0.001) (Table 2). Of 9 
dimenstions of the RAND-36, 6 differed significantly between the patients with 
and without difficulties in sexual activity. Patients who perceive difficulties had 
significant lower QoL scores on social functioning, physical and emotional role 
limitations, mental health, vitality and general health. 
In multivariate analyses, living with a partner (OR 3.76, 95%, CI 2.58-5.48), 
younger age (OR 0.96, 95% CI 0.94-0.97)), male gender (OR 3.08, 95% CI 2.10-
4.43), overall wellbeing (OR 1.13, 95% CI 1.00-1.27), and physical (OR 1.06, 95% 
CI 1.06-1.08) and emotional QoL (OR 1.07, 95% CI 1.03-1.10) were 
independently associated with difficulties in sexual activity caused by HF that 
prevented patients from living as they wanted (Table 3). 
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Table 2. Quality of life scores of patients with and without difficulties in 
sexual activity 
No difficulties With difficulties 
p-value 
(n=412) (n=380) 
Ladder of life 
Well-being 6.4 ± 1 .6 6.2 ± 1 .6 .068 
1\tl.in11esota living 111ith Hearl Failure 
Physical dimension 1 7  ± 1 1  23 ± 1 1  <.001 
Emotional dimension 6 ± 6  9 ± 6  <.001 
RAND-36 
Physical functioning 44 ± 28 41 ± 26 . 1 52 
Social functioning 61 ± 30 52 ± 29 < .001 
Role limitations Physical 26 ± 37 1 5  ± 30 <.001 
Role limitations Emotional 54 ± 46 41 ± 45 <.001 
Mental health 72 ± 20 67 ± 21 .002 
Vitality 5 1  ± 23 44 ± 22 <.001 
Bodily pain 75 ± 28 72 ± 29 .066 
General health 46 ± 20 42 ± 1 8  .008 
Health change 35 ± 28 33 ± 3 1  . 1 73 
Table 3. Adjusted associations between patients with and without 




Living with a partner 
Minnesota living with heart 
failure-Physical dimension 
:Minnesota living with heart 
B (SE) 
-.04 (0.01) 
1 . 1 3  (0.20) 
1 .32 (0. 1 9) 
-.06 (0.01) 
failure-Emotional -.06 (0.00) 
dimension 
Ladder of life . 12  (0.06) 
95% Cl for Odds Ratio 
OR Lower Upper p-value 
.96 .94 .97 <.001 
3.08 2 . 10  4.43 <.001 
3.76 2.58 5.48 <.001 
1 .06 1 .04 1 .08 <.001 
1 .07 1 .03 1 . 1 0  <.001 
1 . 1 3  1 .00 1 .27 .049 
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All patients 
(n=SSS) 
I 1 month 
With sexual No sexual 
difficulties difficulties 
(n=270) (n=285) 
I 1 8 months 
I I I I 
Continued Recovered New onset No difficulties difficulties difficulties difficulties 
(n=190) (n=80) (n=78) (n=207) 
Figure 1. Flowchart of patients and course of perceived difficulties in sexual 
activity. 
3.3 Course of difficulties in sexual activity 
At 1 month after discharge, 270 of the 555 patients (49%) reported difficulties in 
sexual activity, and at 18 months after discharge, 268 (48%) patients reported 
difficulties in sexual activity in some degree. Analyses over time show that of the 
270 patients who reported sexual difficulties at 1 month after discharge, 80 
patients (30%) recovered at 18 months follow up and 190 (70%) patients still 
reported difficulties. Of the 285 patients who did not report sexual difficulties at 
baseline, 207 (73%) did not report difficulties at 18 months as well, and 78 (27%) 
developed difficulties during 18 months follow up (new onset difficulties) (Figure 
1 ). Compared to patients without difficulties, patients who developed sexual 
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difficulties were more often male (55% vs. 78%, p<0.001) and living with a 
partner (44% vs. 74%, p<0.001). Furthermore, patients who remained without 
difficulties, improved in QoL over time compared to new onset patients whose 
QoL scores did not change or worsened (change scores physical QoL -3.5 vs. 0.9, 
p=0.001, change scores emotional QoL: -2.2 vs. 0.04, p=0.002, changes scores 
wellbeing: 0.42 vs. -0.01, p=0.047). The number of hospital admissions did not 
differ between both groups (0.24 vs. 0.32, p=0.376). 
4. Discussion 
To our knowledge, this is the first study to explore the relationship between 
perceived difficulties in sexual activity caused by HF and a considerable number of 
demographic variables, clinical variables, and QoL aspects and reports the course 
of difficulties in sexual activity, in a representative population of patients with HF. 
Almost 50% of patients with HF perceive difficulties in sexual activity due to their 
disease, and most (70%) of these patients continued to report difficulties after an 
18 month recovery period. This was a remarkable difference with perceived 
difficulties experienced by 20% to 30% of healthy older people.22 
Male gender, younger age, and living with a partner were independently associated 
with perceived sexual difficulties. Patients who reported difficulties in sexual 
activity had significant lower disease-specific QoL and overall well-being 
compared with patients who did not perceive sexual difficulties. We did not find 
an independent relation of difficulties in sexual activity to disease severity markers 
such as NYHA, L VEF or B-type natriuretic peptide, or beta blocker use. In 
addition, the use of tobacco or alcohol, having diabetes, and number of 
medications, as described in other studies, were not found to be related to sexual 
activity,9,1 2  possibly because of an older and larger study population. 
We believe that the present analysis is clinically relevant and extends previous 
studies by using a large group of older male and female patients with HF. Previous 
studies assessing the relationship between patient characteristics and sexual 
functioning used small and predominantly male patient groups.9,1 2  
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Our study is also unique in the sense that we chose to include both patients with 
and without a partner. Of course, we realize that having a partner is strongly 
associated with the perception of sexual problems, because patients who have a 
partner can be expected to be confronted more often with those problems as part 
of their daily life.23 However, our study also showed that 1 8% of the patients who 
perceived difficulties with sexual activity were living without a partner; thus, not 
only patients with a partner experience sexual difficulties caused by HF that 
prevent them from living as they want. It is important to report the prevalence in 
dysfunction in both patients with and without a partner, because patients might 
define sexual activity broader than having intercourse (eg, masturbation) and single 
patients might worry about their (future) sex life. The second strongest variable 
related to difficulties in sexual activity was male gender. Of the patients who 
perceived difficulties in sexual activity, 76% was male. Endothelial dysfunction is 
prevalent in patients with HF and one of the main common denominators for 
erectile dysfunction, but not in female sexuality.8,24 Therefore problems in 
sexuality can be assumed to affect the male sexual function more than female 
sexual function. Although previous research mainly focused on male sexuality and 
erectile dysfunction,8 our study shows that 24% of the patients who perceive 
difficulties in sexual activity are women. Heart failure symptoms such as dyspnea, 
fatigue, and exercise intolerance can be assumed to affect sexuality in both male 
and female patients. 
We rather uniquely report on the course of perceived difficulties with sexual 
activities. We found that, at both time points, approximately half of the patients 
reported difficulties with sexual activities caused by symptoms of HF. However, 
we also demonstrated that 30% of the patients, who reported difficulties at 1 
month after discharge, did not report difficulties in sexual activity at follow up. 
Possible reasons for the decrease in difficulties might be stabilization of HF, 
increased physical capacity during recovery, or possible use of PDES inhibitors. 
However, at the same time, we found that 27% of the patients without difficulties 
at 1 month after discharge did perceive sexual problems at 1 8  months follow-up 
and that, in 70% of the patients with difficulties, these difficulties remained. 
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Patients who continue to be without difficulties improved in QoL over time, in 
contrast to new onset patients, whose QoL stayed the same or worsened. These 
findings emphasize that sexual concerns need to be discussed more than once 
during treatment and should become an integral part of HF management and 
patient education.25,26 It is known that, although the most of the health care 
providers feel a responsibility to discuss sexual concerns with their patients, many 
do not address these concerns in their daily practice.27,28 
Several limitations of this study should be considered. First, perceiving difficulties 
in sexual activity was based on a single question from a larger QoL questionnaire. 
This results in a global measurement of difficulties in sexual activity. However, our 
results are comparable with studies that used more extensive questionnaires on 
sexual functioning.9 Second, the specific question on sexual activity concerns 
perceived difficulties with sexuality because of HF and that prevents them from 
living as they want. We do not know if these patients actually have sexual 
problems, we only know that their HF affects their sexuality. Sexual activity could, 
for example, be affected by HF symptoms such as fatigue or dyspnea, which is not 
stated as an actual sexual problem. Therefore, we do not know if these patients 
actually have sexual problems, for example, problems with erection, or that other 
factors, such as HF symptoms, make their sexual activities difficult and prevent 
them from living as they want. When interpreting the results, it should also be 
taken into account that not necessary patients who are male, living with a partner, 
and younger of age actually have more difficulties in sexuality. It can be expected 
that these characteristics are associated with a higher likelihood of reporting 
difficulties with sexual activities that prevent the person from living as he/ she 
wants. Finally, our findings show that difficulties in sexual activity are related to 
QoL. Our data do not provide insight in the cause and effect in this relationship. 
Patients with difficulties in sexual activity can be expected to have a lower QoL, 
because of these difficulties. However, one can also imagine that a worse QoL can 
influence sexual relations because of functional impairment and emotional 
problems. 
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This study provides an important step toward understanding the occurrence of 
sexual problems in patients with HF. Perceiving difficulties in sexual activity 
caused by HF and preventing patients from living as they wanted affect many 
patients with HF. Furthermore, these difficulties continue over time and influence 
the QoL of these patients. Therefore, it is of great importance to counsel patients 
with HF repeatedly on sexual activity during their treatment. 
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Abstract 
Objectives: To investigate perceived sexual problems in a large group of younger 
and older patients with heart failure (HF), with and without a partner, focusing on 
a broad range of perceived sexual problems, and compare this with a sample of 
healthy community dwelling elderly. 
Design: Cross-sectional study. 
Setting: 17 HF clinics and general practices in the Netherlands. 
Participants: 438 Patients with HF and 459 healthy community-dwelling elderly 
Main outcome measures: Differences in sexual functioning, related factors and 
perceived causes of sexual problems between patients with HF and healthy 
community controls. 
Results: In total, 59% of HF patients reported sexual problems, mostly being 
problems with erectile function. HF patients with a partner (67%) and younger 
patients (65%) reported significantly more sexual problems than healthy 
community controls (resp. 58%, p=0.011 and 53%, p=0.011). Multivariate 
analyses show that sexual problems in HF patients with a partner were more 
common in men (OR 2.73, 95% CI 1.572 to 4.753) and in those with a 
prescription of beta-blockers (OR 2.00, 95% CI 1.10 to 3.586). In younger 
patients, sexual problems were independently associated with male gender (OR 
3.21, 95% CI 2.099 to 4.908) and having a partner (OR 2.00, 95% CI 1.283 to 
3.110). HF patients mainly attribute their sexual problems to symptoms of HF. 
Conclusion: Sexual problems are common in patients with HF, particularly in 
younger patients and those with a partner. Since patients attribute their sexual 
problems mostly to heart failure symptoms, adequate treatment and education of 
HF patients is needed. 
Sexual problems in elderly male and female patients I 109 
1. Introduction 
Sexuality is a relevant component of quality of life, irrespective of a chronic condition 
such as heart failure (HF). Consequences of symptoms, treatment or psychological 
burden from being chronically ill or having a cardiac disease influences the quality of 
life of patients, and can affect sexual performance or cause sexual problems. 1 
Symptoms of dyspnoea and fatigue may hinder the possibility of being active, and 
chest pain might cause patients to feel anxious during sexual activity.2 Patients and 
their partners might fear deterioration as a result of sexual activity and death during 
intercourse.3 Decreased frequency of sex, less satisfaction and loss of sexual interest 
were reported in HF patients at 3 and 9 months after a hospital admission.4 
In earlier small studies sexual function of HF patients was studied in relatively 
young, married, and predominantly male patients, mainly addressing the 
prevalence of erectile dysfunction, and possibilities for treatment.5•8 We recently 
reported that impaired sexuality is reported in approximately 50% of both male 
and female HF patients, as well as patients with and without a partner.9 
Considering the demographical characteristics of HF patients in daily practice, in 
which 50% is female and 30-50% are living alone, 10·1 2  more in-depth information 
is needed on the problems of both female and male patients, and patients with or 
without a partner. 
At the same time it is known that there are age related changes in sexuality caused 
by normal hormonal changes, vascular damage, or muscular weakness that are 
independent of HF, 13 so it should be recognised that sexual problems might be 
part of the aging process, and not only be caused by HF. To contribute further to 
research on this subject, it is therefore important to have insight in the nature and 
cause of sexual problems of HF patients compared to healthy community-dwelling 
elderly people. 
To get a clinically relevant perspective on the sexual problems of patients with HF, 
we aimed to study differences in sexual functioning, perceived causes, and related 
factors of sexual problems between HF patients and healthy community controls, 
both older and younger, and with and without a partner. 
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2. Methods 
The present study has a descriptive cross-sectional design. The sample consisted 
of HF patients who completed the follow-up of the Coordinating study evaluating 
Outcomes of Advising and Counselling in Heart failure (COACH) and a reference 
group of healthy community controls.1 4, 1 5 
2.1 Study population 
2.1.1 Heart failure population 
All patients were previously enrolled in the COACH study, a Dutch multicenter, 
randomized, controlled trial evaluating the effect of education and support in HF 
patients. Patients were included in the study during a hospitalisation for HF (New 
York Heart Association functional class II-IV), with HF as the primary diagnosis. 
Patients were followed during 18 months in which data on readmission and 
mortality were collected. During the last interview, 18 months after inclusion, 751 
patients were alive and asked if they were willing to complete a questionnaire on 
sexual function at a later time point, and return it in a pre-stamped envelope. The 
Central Ethics Committee approved the study protocol and the amendment of the 
additional questionnaire on sexual function (METc 2002/047: Amendment 3). All 
patients provided informed consent. The study was performed in accordance with 
the principles outlined in the Declaration of Helsinki.14, 1 5 
2.1.2 Healthy community controls 
Nine local district council offices in different areas in The Netherlands were asked 
for a random sample of addresses of 500-1000 subjects of at least 55 years of age 
who were not living at the same address. Between J uly and August 2005, 5500 
questionnaires were distributed accompanied by a letter in which the subjects were 
invited to complete the questionnaire, and return it in a pre-stamped envelope. 
Anonymity and confidentially was guaranteed. Participants rated their health on a 
self-reported questionnaire on 19 active medical problems. From the 2512 elderly 
people, 1695 (67%) answered the questions on sexual function. Of these, 459 
(27%) reported no health problems, and were selected for our comparison. 
2.2 Study measures 
2.2.1 Sexual problems 
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All participants were asked if they had problems with regard to interest, arousal, 
erection, vaginal dryness, orgasm or other problems. When answering affirmative 
to one or more of these questions they were considered as having sexual 
problems. Seven additional questions were added to describe the perceived cause 
of their sexual problems: shortness of breath, fatigue, pain, anxiety, anxiety of the 
partner, medication, and limited circulation. All additional questions were 
dichotomous with yes/ no answer categories. The content, wording and validity of 
the questions were assessed by healthcare professionals, researchers and five 
patients with HF. 
2.2.2 Importance and satisfaction with sex 
All participants were asked to rate the importance and satisfaction with their 
sexual activity at this particular moment on a visual analogue scale ranging from 0 
to 10 (0, very unimportant to 10, very important) . Patients were also asked to rate 
the importance and satisfaction before their HF was diagnosed. 
2.2.3 Sexual adjustment 
Patients with HF completed the sexual adjustment subscale (SAS) of the 
psychosocial adjustment to illness scale. 1 6  This subscale has been used in previous 
studies in HF patients, describing shifts in the quality of sexual relations due to the 
current illness or treatment, and is composed of six items; change in sexual interest 
since illness, change in frequency of sexual activity, change in satisfaction, 
problems with sexual performance, arguments related to sex, problems with 
spouses. Each item has a scoring range of 0-3. For the SAS the total score ranges 
from 0 to 18. Low scores reflect good adjustment, whereas high scores indicate 
poor adjustment. The validity and reliability of the instrument has been established 
in a variety of clinical populations. The internal consistency of the subscales is 
acceptable with Cronbach alphas ranging from 0.74 to 0.80 in HF patients.4,1 7 Due 
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to the orientation on adaptation to disease, the SAS was not administered to the 
community controls. 
2.2.4 Demographic and clinical characteristics 
Data on demographic and clinical characteristics were collected from chart review, 
interviews and questionnaires. Depressive symptoms were measured with the 
Center for Epidemiological Studies Depression scale (CES-D). A total sum score 
is used (0-60), with higher scores indicating more depressive symptoms. 18, 19 
2.3 Statistical Analyses 
Descriptive statistics were used to characterise both samples. For continuous 
variables means and standard deviations, and for categorical variables, frequencies 
with percentages were used. Differences on sexual problems, and importance and 
satisfaction with sexuality between community controls and patients with HF were 
tested by Chi2 tests and an independent sample t-test. Importance and satisfaction 
with sexuality in patients with HF now and before HF was tested with a paired 
samples t-test. 
Differences in demographic and clinical characteristics between patients with and 
without sexual problems were univariate tested with independent sample t-tests 
and Chi2 tests. A multivariable logistic regression analysis was performed to define 
the independent association between sexual problems and demographic and 
clinical characteristics. The multivariate model was built by entering those 
variables that had a univariate p<0.15, and retaining those variables with p<0.05 in 
the final model. As previous studies showed that age and having a partner is 
associated with sexual problems, in order to gain more insight into sexual 
problems, we performed analyses independently for respondents of 65 years and 
younger and older than 65 years, and for respondents with or without a partner. 
The cut-off age of 65 years was decided on based on the mean age of both the 
patient and healthy community controls groups. Sixty-five years was about the 
median of the four values, and the value in which all groups still consisted of a 
considerable number of respondents for statistical analyses. Having a partner was 
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defined as 'married-living together ', 'not married-living together', and 'having a 
partner-not living together '. Furthermore, in the total group the interaction 
between age and having a partner was included in the model. 
3. Results 
3.1 Patient characteristics 
In total, 438 patients of the 751 HF patients (59%) returned completed 
questionnaires on sexual function. Patients who returned the questionnaires were 
slightly younger compared to those who did not return the questionnaires (68 (± 
12) vs. 71 (± 11), p=0.001), were more often living with a partner (68% vs. 53%, 
p<0.001), and were more often in an intervention arm of the COACH study (care 
as usual 29% vs. 37%, basic intervention 34% vs. 33%, intensive intervention 38% 
vs. 31%, p=0.039). No differences were found with regard to gender. 
Of the 438 patients 68% (298) had a partner. The mean age was 68 years (± 12), 
and 62% were men. Patients had a mean left ventricular ejection fraction of 33% 
(± 14), and were prescribed the standard HF medications; 74% of patients were 
prescribed a beta-blocker at the time of this study (fable 1). 
Of the 459 healthy community controls, 87% (401) had a partner, with a mean age 
of 64 years (± 7), and 67% were men. In total, 13% of the healthy controls (n=58) 
did not have a partner, these had a mean age of 65 years (±8), and 55% were men. 
Table 1. Patient characteristicsa 
Age, mean (SD), y 
Male 
Intervention group 
Care as usual 
Basic intervention 
Intensive intervention 
Length of relationship, mean (SD), y 
NYHA III-IV at 1 8  months 













1 25 (29) 
148 (34) 
1 65 (38) 
38 (1 4) 
1 27 (32) 
33 (14) 
1 68 (38) 
37 (8) 











81  (27) 
1 02 (34) 
1 1 5  (39) 
38 (1 4) 
85 (31) 
32 (14) 





21 8 (77) 
266 (94) 
1 34 (48) 
Without a 65 years and Older than 
partner younger 65 years 
(n= 140) (n= 1 55) (n=283) 
72 (13)* 55 (9) 76 (6)*** 
54 (39)*** 1 00 (65) 1 70 (60) 
44 (31) 38 (25) 87 (31) 
46 (33) 55 (35) 93 (33) 
50 (36) 62 (40) 1 03 (36) 
- 27 (12) 45 (1 1 )*** 
42 (33) 33 (23) 94 (36)* 
33 (14) 30 (14) 34 (14)* 
45 (32) 38 (25) 1 30 (46)*** 
1 5  (1 1)  5 (3) 32 (1 1)* 
36 (26) 24 (1 6) 79 (28)* 
31 (22) 33 (21) 61 (22) 
1 12 (80) 1 33 (86) 221 (78) 
87 (68)* 1 1 1  (77) 1 94 (73) 
1 1 8  (92) 1 30 (90) 254 (96)* 
53 (41) 61 (42) 1 26 (47) 
Table 1. (Continued) Patient characteristicsa 
CES-D score, mean (SD) 
With partner 
Older than 65 years 











a Data are presented as No. (%) of participants unless otherwise indicated 
















Abbreviations: NYHA=New York Heart Association functional class; LVEF=Left Ventricular Ejection Fraction; 
COPD=Chronic Obstructive Pulmonary Disease; ACE/ ARB=Angiotensin Converting Enzyme Inhibitor or 
Angiotensin Receptor Blocker; CES-D=Center for Epidemiological Studies Depression Scale. 
Table 2. Problems and attributed causes in HF patients and community controlsa 
Total group With a partner Without a partner 65 years and Older than 65 
(n=897) (n=699) (n=l 98) younger (n=453b) years (n=439b) 
cc HF cc HF cc HF cc HF cc HF 
(n=459) (n=438) (n=401) (n=298) (n=58) (n= 1 40) (n=298) (n= 1 55) (n= 1 56) (n=283) 
Problems in 259 
259 (59) 
231 200 
28 (48) 59 (42) 
1 57 101  
99 (64) 
1 58 
sexual function (56) (58)' (67) (53)' (65) (56) 
No interest in 
53 ( 12) 56 (1 3) 47 (12) 40 (1 3) 
sex 
6 ( 10) 1 6  (1 1 )  28  (9) 19  (12) 23 ( 15) 37 (1 3) 
No sexual 
47 (10) 50 (1 1 )  41  (10) 38 (1 3) 6 (10) 12  (9) 29 (10) 21 (1 4) 1 8  (12) 29 (10) 
arousal 
Problems with 52 
1 01 (37) 
46 
83 (38) 6 (1 9) 1 8  (33) 
1 9  
39 (39) 33 (30) 62 (37) 
erection (males) ( 1 7)**' (1 7)*** (1 0)'*' 
Problems with 
vaginal 50 
1 0  (6) 
45 
1 0  (12) 5 (1 9)'*' 0 (0) 36 (33)" 5 (9) 
1 4  
5 (4) 
lubrication (31 )*** (34)*'' (30)**' 
(females) 
Problems with 
36 (8) 41 (9) 35 (9) 34 (1 1 )  
orgasm 
1 (2) 7 (5) 1 6  (5) 1 4  (9) 1 9  (12) 27 (10) 
Other problems 57 (12) 42 (10) 50 (1 3) 28 (9) 7 ( 12) 1 4  (10) 44 (1 5) 20 ( 13) 1 3  (8) 22 (8) 
Table 2. (Continued) Problems and attributed causes in HF patients and community controls3 
Causes of changes 











Total group With a partner Without a partner 65 years and Older than 65 
(n=897) (n=699) (n= 1 98) younger (n=4536) years (n=4396) 
CC HF CC HF CC HF CC HF CC HF 
(n=459) (n=438) (n=401) (n=298) (n=58) (n=140) (n=298) (n= 155) (n=1 56) (n=283) 
2 (0)* 86 (20) 2 (1 r·· 68 (23) 0 (0)* 1 8 (1 3) 1 (0)**' 32 (21) 1 (1 )'** 54 (1 9) 
37 (8)*** 87 (20) 35 (9)**' 75 (25) 2 (3) 1 2  (9) 22 (7)*** 44 (28) 1 5  (10) 43 (1 5) 
20 (4) 1 3 (3) 1 8  (5) 1 0  (3) 2 (3) 3 (2) 1 2  (4) 5 (3) 8 (5) 8 (3) 
21 (5) 26 (6) 1 8 (5) 22 (7) 3 (5) 4 (3) 8 (3)* 16 (10) 1 3 (8)* 1 0  (4) 
23 (5) 1 3 (3) 23 (6) 1 3  (4) 1 3 (4) 6 (4) 1 1  (7)* 7 (3) 
9 (2)*** 43 (1 0) 8 (2) ... 37 (12) 1 (2) 6 (4) 3 (1 r·· 22 (14) 6 (4) 21 (7) 
26 (6)* 48 (1 1) 24 (6)'* 42 (14) 2 (3) 6 (4) 1 6  (5)* 1 8  (12) 1 0  (6) 30 (1 1) 
a Data are presented as No. (%) of participants 
b Jv1issing data on age of 5 community controls 
*p <0.05 ***p<0.001 
Abbreviations: CC=Community Controls; HF=Heart Failure patients 
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3.2 Sexual problems 
In total, 59% of the patients reported problems with sexual function, compared to 
56% of the healthy community controls (Table 2). Patients reporting sexual 
problems were younger (67 vs. 70 years, p=0.025), were more often men (75% vs. 
43%, p<0.001), were diagnosed with ischemic HF (44% vs. 31%, p=0.006), had a 
partner (77% vs. 55%, p<0.001), and had more often a prescription of beta­
blockers (80% vs. 66%, p=0.002), and lipid-lowering drugs (51 % vs. 37%, 
p=0.007). In multivariate analyses, variables that were independently related to 
reporting sexual problems were male gender, a prescription of beta-blockers, and 
having a partner. The interaction of age and having a partner was not significant 
related to reporting problems (Table 3). 
3.3 Sexual problems in younger and older respondents 
Patients who were 65 years and younger reported significantly more sexual 
problems compared to healthy controls of the same age category, this was not 
found in patients older than 65 years compared to healthy controls. Younger male 
patients reported more often problems with erectile function than the healthy 
controls. However, in both the younger and older respondents female patients 
reported less often problems with vaginal lubrication than female controls (Table 
2). 
Independent of age category, patients rated the importance and their current 
satisfaction of sexuality lower than before their disease, and lower than healthy 
community controls. All patients did perceive sexuality as less important, and were 
less satisfied with their current sexuality than before their HF (Figure 1). 
Younger patients had a mean total score of 6.0, and older patients of 7.5 on the 
SAS, with higher scores reflecting more perceived problems. Most problems, both 
in younger and older patients, were found on the items related to the change in 
frequency of sexual activity, and the least problems on describing arguments with 
their spouses related to their sexual relationship. Shortness of breath and anxiety 
were reported more often as the cause of sexual problems in both younger and 
older patients compared to healthy controls. Younger patients also reported 
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fatigue, medication, and limited circulation more often to be the cause of their 
problems, unlike the older patients, who reported more often their partners' 
anxiety to be the cause of their problems compared to the healthy community 
controls of the same age category (fable 2). 
Different associations were found between sexual problems in younger and older 
patients. In younger patients male gender, and having a partner were 
independently associated with problems in sexual functioning. In older patients 
male gender and a prescription of beta-blockers were independently associated 
with sexual problems (fable 3) . 
3.4 Sexual problems in respondents with and without partner 
Patients with a partner significantly more often perceived sexual problems 
compared to healthy controls. Patients without a partner did not report more 
sexual problems than the healthy controls without a partner. In respondents with a 
partner, male patients reported significantly more problems with erectile function 
than healthy controls (fable 2) . 
Patients had a mean total score on the SAS of 6.8. No differences were found 
between patients with or without a partner. Shortness of breath was more often 
reported as cause of sexual problems in patients than healthy controls, 
independent of having a partner (fable 2) . 
Different associations were found between sexual problems in patients with or 
without partner. In patients with a partner male gender and a prescription of beta­
blockers were independently associated with problems in sexual functioning. In 
patients without a partner male gender, ischaemic HF, a prescription of beta­
blockers, and a higher score on the CES-D were independently associated with 
sexual problems (fable 3) . 
A 
• Community controls (with partner n=140 I without partner n=58 ) 
El Heart failure patients before disease (with partner n=298 I without partner n=140) 






Importance SatIsfact1on Importance Sahsfacbon 
with partner without partner 
B 
• Community cortrols (<65 years n=298 />65 years n,.1 56) 
a Heart fa1h.re patients before disease (<65 years n=1 55 / >65 years n=283) 






mportance Sabsfact1on Importance SatIsfacbon 
65 years and younger older than 65 years 
Figure 1. Importance and satisfaction with sexual activity of community controls and heart failure patients. 
*p<0.05, ***p<0.001. 
A. Respondents with and without a partner. 
B. Respondents younger and older than 65 years. 
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Table 3 .  Multivariate analyses problems in sexual function of HF patients 
B (SE) Odds Ratio (95% CI) p-value 
Totalgro11p (11=438) 
Male 1 .4 (0.2) 3.93 (2.50 to 6 . 18) < .001 
Beta-blocker at 18 months 0.7 (0.3) 2.05 (1 .26 to 3.33) .004 
Having a partner 0.6 (0.2) 1 .  73 (1 .08 to 2. 78) .02 
Patients 1vith a partner (,1=298) 
Male 1 .0 (0.3) 2.73 (1 .57 to 4.75) < .001 
Beta-blocker at 1 8  months 0.7 (0.3) 1 .99 (1 . 10  to 3.59) .02 
Patients 1vitho11t a partner (11= 140) 
Male 2.0 (0.5) 7.37 (3.05 to 1 7.79) < .001 
Ischemic HF 1 .4 (0.5) 3.99 (1 .54 to 1 0.34) .004 
Beta-blocker at 1 8  months 1 . 1 (0.03) 3 . 12 (1 . 1 8  to 8.24) .02 
CES-D score -2.9 (0.7) 1 .05 (1 .00 to 1 . 1 1) .04 
Patients S.,65 years (11= 155) 
Male 1 .2 (0.2) 3.21 (2.10  to 4.91) <.001 
Having a partner 0.7 (0.2) 2.00 (1 .28 to 3.1 1)  .002 
Patients > 65 years (n=283) 
Male 1 .6 (0.3) 5. 1 8  (3.00 to 8.96) < .001 
Beta-blocker at 18 months 1 .0 (0.3) 2.60 (1 .43 to 4.73) .002 
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4. Discussion 
Our results show that sexual problems are common in patients with HF. 
Considering these problems in the total population of patients, without taking age 
or marital status into account; these problems are comparable with healthy 
community controls. However, when looking specifically to participants with and 
without a partner, and older and younger participants, HF patients with a partner 
and younger patients reported a significant reduction in their satisfaction with 
sexuality, and perceived more sexual problems compared to healthy community 
controls. In younger patients male gender and having a partner were 
independently associated with problems in sexual functioning. In patients with a 
partner male gender and having a prescription for beta-blockers were associated 
with sexual problems. Based on previous studies, we expected more reported 
sexual problems in the HF population. This was not the case. A possible 
explanation could be that these studies predominantly focused on younger male 
patients and patients with a partner.5-8 Our total study sample also included older 
female patients, and patients without a partner. Our results show that a large 
percentage of these patients do report sexual problems; however, it did not differ 
significantly from the healthy community controls. 
This is the first study with a considerable patient sample that examined specific 
and in-depth sexual problems in HF patients compared to healthy community 
controls. It is known that changes in sexuality might be part of the aging process 
(hormonal changes, vascular damage, or muscular weakness) and are not only 
caused by HF.13 In order to gain more insight into age-related sexual problems, we 
chose to analyse data separately for respondents older and younger than 65 years. 
Our study is also unique in the sense that we chose to include male and female 
patients, and patients both with and without a partner. Of course, we realize that 
having a partner is strongly associated with the perception of sexual problems, as 
patients who have a partner can be expected to be confronted more often with 
those problems as part of their daily life.20 Therefore, we analysed participants 
with and without a partner separately. 
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Patients and their partners might worry about sexual problems. Our study 
confirmed previous reports of the higher prevalence of erection problems in 
cardiac patients compared to a non-cardiac population.2 1 A decreased frequency 
and decreased interest were reported by patients as result of their HF. Although 
more male patients perceive sexual problems, we also found a large number of 
women (25% of the total group) reporting sexual problems, suggesting that the 
main focus on men in research regarding sexual problems in cardiovascular disease 
does not seem appropriate.22 In general, HF symptoms like dyspnoea, fatigue, and 
exercise intolerance can be assumed to affect sexuality in both male and female 
patients. This seems to be confirmed by our results, which show that all patients 
attribute their sexual problems to their HF symptoms, and therefore it is 
important to address the possible influence of HF and HF-medication in patient 
education and treatment. In particular, the attribution of sexual problems to 
medication can lead to non-compliance with the treatment regimen. In our study 
female patients also reported problems with arousal, interest, and orgasms. Only a 
minority of the female patients reported problems with vaginal lubrication, which 
was significantly less often reported compared to healthy controls. 
We found an independent relationship between prescriptions of beta-blockers and 
sexual problems in patients with and without a partner, and also in older patients. 
Until now results from studies addressing the relationship between beta-blocker 
use and sexual problems are incongruent.23,24 Animal studies have reported that 
beta-blockers such as propanolol may induce erectile dysfunction through central 
and peripheral (genital) effects as it increases the latency to ex copula ejaculation, 
the latency to initial erection, and reduces the number of erectile reflexes.25 
However, Silvestri et al. suggest that reports of erectile dysfunction in patients 
receiving beta-blockers may be mostly psychological in origin as it is more 
frequent in patients knowing the side effect of the drug, and it is reversed in the 
majority of cases by placebo.24 
Despite earlier hypothesising about the possible anxiety of patients affecting the 
return to sexual activity, only 6% of the HF patients described their own anxiety, 
and 3% the anxiety of their partner as a reason for sexual problems.2 Depressive 
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symptoms are known to be related to sexual problems,26,27 and we found that 
patients with sexual problems had higher CES-D scores, and depressive symptoms 
were independently related to sexual problems in patients without a partner. 
Furthermore, it is interesting to note that HF patients rated the importance and 
satisfaction with their current sexuality significantly lower than before their 
disease. Looking back on their sex life before their HF the importance and 
satisfaction with sexuality was the same as the community controls. However, 
patients perceive sexuality as less important, and were less satisfied with current 
sexuality (eg, having diagnosed HF) than community controls. This possibly 
reflects adaption of priorities and expectations in life when living with a chronic 
disease.28 
Several limitations of this study should be considered. First, the list of characteristics 
of the community controls was limited, and only included age, gender, having a 
partner and the presence of medical problems. Given the age group, a high 
percentage of morbidity would be expected, with sexual problems as a possible 
consequence. Therefore, in order to make a representative comparison, community 
controls who reported health problems were excluded from our analyses. A second 
limitation of this study is the response of the survey, which was 59%. Although this is 
an acceptable response, and comparable to other surveys, this needs to be taken into 
account because it is reasonable that patients with problems were more motivated to 
return the questionnaires. On the contrary, it can be imagined that patients have 
some reluctance in reporting sexual problems, even in an anonymous survey. Several 
studies on the accuracy of self reports of sexual behaviour have shown that a survey 
design provides lower reports of sensitive behaviours compared to several different 
interview techniques.29,'ll1 Therefore, it is also reasonable to suggest that the number 
of patients actually having problems with sexual functioning is higher than the 
number of patients who report having problems. 
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4.1 Implications for clinical practice 
Patients with HF, both male and female, with a partner and younger patients 
experience more sexual problems than healthy community-dwelling elderly people. 
However, also a large percentage of older patients and patients without a partner also 
report sexual problems, and all patients attribute these problems to HF-related 
symptoms. These findings emphasise that sexual health needs to be discussed with all 
patients with HF during treatment, and should become an integral part of HF 
management and patient education. Healthcare providers should create an 
environment where patients feel comfortable enough to talk about their concerns, in 
the confidence that these will be addressed. 
4.2 Implications for further research 
Sexual problems in patients with HF are more often reported than to be expected as 
part of the aging process. Further research is needed on interventions to improve 
sexual activity, including sexual counselling. These studies should not only address 
younger and male patients, but also include female and older patients. Furthermore, 
future research on pharmacological and non-pharmacological interventions should 
include sexual activity and sexual function, in order to gain more insight into the 
effects of the treatment on sexual health. 
5. Conclusions 
Patients with HF with a partner and younger patients experience significantly 
more sexual problems than healthy community controls. In addition, a large 
percentage of older patients and patients without a partner report having sexual 
problems, and all patients attribute these to HF-related symptoms. Therefore, 
healthcare providers need to discuss the possible consequences of HF, HF 
symptoms and HF medications on sexual health with their patients on a regular 
basis, in order to help patients cope with their sexual problems. 
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Abstract 
Objectives: We sought to examine the current practice of discussing sexual health 
by heart failure ( HF) nurses, and to explore which barriers prevent nurses from 
discussing sexuality. 
Methods: The Nurses' Survey of Sexual Counseling of Myocardial Infarction 
Patients and a list of berriers were used to form a questionnaire, which was sent to 
all HF clinics (n= 1 22) in The Netherlands. 
Results: The majority (75%) of nurses (n=146) felt a certain responsibility to 
discuss patients' sexual health. However, in practice, 61 % of the nurses rarely or 
never addresses sexuality. Barriers that prevented nurses from addressing sexuality 
and that differed between nurses who do (n=58) and do not (n=88) discuss 
sexuality include a lack of organizational policy (49% vs. 79%, respectively; 
p<0.001), lack of training (43% vs. 80%, respectively; p<0.001), and not knowing 
how to initiate the subject (24% vs. 72%, respectively; p<0.001). Nurses preferred 
to address sexuality during a follow-up visit or when discussing medication. 
Conclusions: Although HF nurses feel responsible for discussing sexuality, this 
topic is rarely addressed in clinics. Several barriers were identified, relating to 
personal, patient, and organizational factors. 
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1. Introduction 
Sexual problems are common among both male and female patients with heart 
failure (HF). 1 .2 Problems reported by patients with HF include a decrease in sexual 
interest, a decrease in the frequency of sexual activity, severe negative changes in 
sexual performance, and a loss of pleasure or satisfaction related to sexual activity. 
Furthermore, a significant proportion of men with HF experience erectile 
dysfunction. 1 - .1 Patients attribute their sexual problems to their HF. In addition, HF 
medications may also lead to sexual problems. The use of beta-blockers in particular 
is known to exert a possible detrimental effect on sexuality, although studies 
addressing the relationship between beta-blockers and sexual problems have been 
incongruent. 4,5 
Patients with HF and their partners have expressed a wish to receive information 
about resuming sexual activity after a diagnosis of HF.6 However, when trying to 
address this topic, patients experience barriers, such as the perception that individual 
practitioners do not appear experienced enough to understand the patient's 
problems, or because feelings of shyness and embarrassment prevent them from 
initiating discussions.7 In this respect, nurses play an important role in assessing the 
effects of HF on sexuality with both patients and their partners. This becomes even 
more apparent when taking into account the fact that HF nurses are becoming more 
and more involved in the long-term management of patients with HF. 
Although international HF guidelines recommend that healthcare providers discuss 
sexual health with their patients, previous studies showed that although healthcare 
providers do feel responsible for discussing sexual health, they rarely discuss this 
topic with their patients in practice.8 1 1 To improve patient care in this area, it is 
important to learn which barriers prevent nurses from discussing sexual health with 
their patients. A study of cardiac rehabilitation staff showed that barriers included 
lack of training, the feeling that the patient was not yet ready to discuss issues related 
to sexual health, and a general lack of knowledge concerning sexual health. 1 1  
Unfortunately, little information is available on the current practice of discussing 
sexual health and providing sexual counselling by HF nurses in The Netherlands. 
Therefore, this study was designed to examine: (1) the current practice of discussing 
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sexual health in HF clinics in The Netherlands and the perceived responsibility of 
nurses to address patients' sexual health; (2) the preferred moment during HF 
treatment to address patients' sexual concerns; and (3) differences in barriers to 
sexual counselling between nurses who do and who do not discuss this topic. 
2. Methods 
2.1 Study participants 
A letter of introduction was sent to all HF clinics in the Netherlands (n=122), 
which included 3 copies of a questionnaire and a freepost return envelope. 12, 13 We 
included three copies because, in general, a maximum of 3 HF nurses works at 
each HF clinic. In the letter of introduction, nurses working at the specific HF 
clinic were asked to complete the (anonymous) questionnaire and return it within 
2 weeks. Non-responders received a reminder in the form of a telephone call after 
3 weeks. Confidentiality was guaranteed to the participants of the study, and 
answers could not be traced back to individual nurses. 
2.2 Questionnaire 
Two questionnaires used in previous studies formed the basis of the current 
questionnaire. These included 2 subscales of the Nurses' Survey of Sexual 
Counseling of Myocardial Patients, and a list of barriers used by Doherty et 
a1. 1 1, 14, 1s 
(1) The subscales for practice and responsibility of the Nurses' Survey of Sexual 
Counseling of MI patients were used in this study: The subscale "Practice" (8 
items) addresses the overall practice of sexual counseling. For example, "In the 
past year, with what percentage of your clients have you assessed their sexual 
health?" Four items were scored on a scale of O to 3, and 4 items were scored on a 
scale of O to 5. The subscale scores ranged from O to 32, with higher scores 
indicating better performance of nurses on sexual counseling in daily practice. To 
clarify the data, the scores on the 6 answer categories were translated into "never" 
What keeps nurses from sexual counseling? I 135 
(0%), "sometimes" (1-20% and 21-40%), and "often" (41-60%, 61-80%, and 81-
100%). 
The subscale "Responsibility" (5 items) addresses the perceived responsibility of 
nurses to provide sexual counseling. For example, "Nurses have a responsibility to 
discuss sexual health with their patients" (responses range from "strongly agree" 
to "strongly disagree"). All items were scored on a scale from O to 4. The subscale 
scores ranged from 0 to 20, with higher scores indicating a greater sense of 
responsibility to provide sexual counseling. Reliability of the subscales was 
assessed using Cronbach's alpha and ranged from 0.89 (practice) to 0.75 
(responsibility). 14 
(2) The list of barriers that prevent nurses from discussing sexual health consisted 
of 16 items, as devised by Doherty et al. 1 1  To gain further insights into other 
possible barriers, 8 additional items on barriers were retrieved from discussions 
among a group of experts (including a cardiologist, a sexologist, HF nurses, and 
psychologists) and added to the list. These included: lack of organizational policy 
(eg, is a protocol on sexual health available?), lack of knowledge on how to initiate 
the subject, the patient's failure to initiate the subject, sexuality as a private matter, 
no feeling of connection with the patient, discomfort in addressing the topic, 
projecting personal feelings on the patient (eg, "I would find it unpleasant 
myself'), and the patient is of the same sex. Scores on each item could range from 
1 ("strongly disagree") to 5 ("strongly agree"). 
In addition, participants had to answer 10 questions on sociodemographics and on 
their professional background. The face validity of the total questionnaire was 
tested in a pilot study by 4 HF nurses. Only editorial changes were effected in 
response to the nurses' answers. 
2.3 Statistical analyses 
Data were analyzed using SPSS, version 16.0 (SPSS Inc, Chicago, IL). Descriptive 
analyses were used to test the sample and the responses to the study variables. 
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Data are presented as means ± standard deviations or percents. We used Chi2 tests 
to compare the perceived barriers of nurses who do discuss sexual health with the 
barriers of nurses who do not discuss sexuality with their patients. A p - value of 
<0.05 was considered statistically significant. For comparing the barriers of nurses 
who do and who do not discuss sexual health, the scores on the barriers were 
recoded to agree ("strongly agree" and "agree") and disagree ("strongly disagree" 
and "disagree"). The answer category "somewhat (dis)agree" was not included in 
the analyses. Scores on discussing sexual health were based on answers to the first 
question of the practice subscale: "How often is sexual health assessed in your 
practice?" The scores were recoded into do discuss ("often" and "occasionally") 
and do not discuss ("rarely" and "never"). 
3. Results 
3.1 Study population 
In total, nurses from 88 of the 122 (72%) HF clinics responded by returning at 
least 1 completed questionnaire. The final sample of respondents consisted of 146 
nurses. The majority of nurses was female (83%), with a mean age of 45 (± 8) 
years (age range 25-61 years). In total, 67% of nurses had a Bachelor's degree, and 
30% reported going on to higher education or workshops on sexuality in nursing 
practice (fable 1 ). 
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Table 1. Nurse characteristics 
Nurses who Nurses who 
Total do discuss do not discuss 
p-value 
(n=146) sexuality sexuality 
(n=58) (n=88) 
Female gender 83% 81% 88% .236 
Age 45 ± 8 45 ± 8 46 ± 7 .830 
Marital status 
Married/living with a 
88% 88% 87% 
partner 
Never married 9% 12% 7% .353 
Divorced/widowed 3% 0% 6% 
Years in cardiac nursing 
0-5 years 32% 31% 32% 
6-10 years 32% 38% 28% .422 
>10 years 36% 31% 40% 
Highest level of 
education 
Basic nursing training 14% 10% 17% 
Bachelor degree 67% 69% 67% .654 
Master degree 5% 5% 5% 
Other 14% 16% 11% 
Education in sexual 
30% 41% 22% .012 
counseling 
3.2 Practice and responsibility 
The subscale "Practice" had a mean score of 10 (± 4) (range, 2 to 24; higher 
scores indicate a better performance of nurses for discussing sexual health in daily 
practice) . When looking at specific items, 1 % of nurses reported that they 
frequently assessed sexual health with their patients, 38% did so occasionally, 53% 
did so rarely, and 8% never assessed sexual health with their patients. 
Furthermore, 50% of nurses never referred patients with questions about sexuality 
to other professions (Figure 1 ), whereas 49 % sometimes did so. 
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The subscale "Responsibility" yielded a mean score of 15 (- 2) (range, 7 to 20, 
higher scores indicate a greater sense of responsibility among nurses to initiate 
sexual counseling). In total, 75% of nurses agreed that they have a responsibility to 
discuss sexual health with their clients; whereas 11 % disagreed, and 14% were not 
sure. Moreover, 37% reported that initiating a discussion on sexual health with 
patients is usually appropriate, whereas 5% of nurses stated that initiating such a 
discussion is always inappropriate (Figure 2). 
No significant differences in background variables were evident between nurses 
who do and nurses who do not discuss sexual health with their patients. However, 
significantly more nurses who do discuss sexual health had received education on 
sexual counseling, compared with nurses who do not discuss sexual health (41 % 
vs. 22%, respectively; p=0.012) (fable 1). 
_-\,  
Listening to clients' concerns 
_-\nswering clients' questions 
Teaching about modifications due to 
disease or treatment 
B. 
_ \ssessment of clients' sexual health 
0° 0 
D Never 
Referral to sexual counselling 
Provided information on sexuality 
Offered to discuss sexual concerns 
20° 0 
• Rarely 
40° '0 60° O 
D Occasionally 
80° 0 100° 0 
D Frequently 
.-\ssessed sexual health _________________ ....__ _ _, 
20° 0 
• Never 
40° 0 60° 0 
o Sometimes 
Figure 1. Practice of discussing sexual health by HF nurses. 
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Is it appropriate for nurses to initiate 
discussion of sexual concerns? 
Is it appropriate to discuss sexual health 
when the client initiates? 
How often should nurses tell they are 
available to discuss sexual concerns? 
0° 0 20% -1-0° 0 60° 0 80° 0 1 00° 0 
• Never • Seldom D Sometimes D Usually D _-\lways 
Nurses have a responsibility to discuss 
sexual concerns 
In most situations it is inappropriate for 
nurses to discuss sexual concerns I I  
0° 0 20% 40° 0 60° 0 80° 0 100° 0 
• (Strongly) agree D Not sure D (Strongly) disagree 
Figure 2. Perceived responsibility of HF nurses to discuss sexual health. 
3.3 Preferred moment of discussing sexual health 
The majority of nurses (74%) agreed that sexual health should be assessed during a 
follow-up visit at the HF clinic or when discussing medication with the patient 
(72%). Thirty percent of nurses felt that sexual health should be discussed during 
the first visit to the HF clinic, 34% preferred to discuss sexual health during 
cardiac rehabilitation, and 13% preferred to address this topic during hospital 
admission (Figure 3). 
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Rehabilitation First visit Follow-up visit 
outpatient clinic outpatient clinic 
Figure 3. Preferred moment of discussing sexual health. 
3.4 Barriers to discussing sexual health 
Discussing 
medication 
The most prominent barriers that deterred nurses from discussing sexual health 
with their patients included a lack of organizational policy (67%), a lack of training 
(42%), issues relating to culture and religion (40%), and the age of the patient 
(39%). Barriers mentioned in the questionnaire that did not keep nurses from 
discussing sexual health included: (1) they do not perceive counseling to be their 
task (3%), (2) the patient is of the same sex (0%), and (3) the patient is of the 
opposite sex (1 %). 
We looked in more detail at the differences in barriers between nurses who 
reported that they do discuss ("often" and "occasionally") sexual health with their 
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patients (n=58) and those who do not discuss' ("rarely" and "never") this topic 
(n=88). 
Nurses who reported discussing sexual health with their patients mentioned 
several barriers to addressing this topic: issues related to culture and religion 
(68%), issues related to language and ethnicity (56%), patients too ill to address 
their sexual health (54%), sexuality not seen as a problem by the patient (53%), 
and a lack of organizational policy (49%). Nurses who rarely or never address 
sexual health mentioned several barriers: a lack of organizational policy (79%), a 
lack of training (80%), failure of the patient to initiate the subject (72%), a lack of 
knowledge on how to initiate the subject (71 %), the older age of the patient (60%), 
and a lack of knowledge on the topic in general (57%). 
Barriers that differed significantly between nurses who do and who do not discuss 
sexual health with their patients included a lack of knowledge (57% vs. 23%, 
respectively; p= 0.001), a lack of training (80% vs. 43%, respectively; p<0.001), not 
knowing how to initiate the subject (71 % vs. 32%, respectively; p=0.001), "I 
would find it unpleasant myself' (18% vs. 2%, p=0.015), "It makes me feel 
uncomfortable" (20% vs. 5%, respectively; p= 0.036), failure of the patient to 
initiate the subject (72% vs. 24%, respectively; p<0.001), and a lack of 
organizational policy (79% vs. 49%, respectively; p<0.001) (Table 2). 
Table 2. Barriers withholding nurses who do and do not discuss sexual health with their patients 
Total group Nurses who do Nurses who do Barrier discuss sexuality not discuss p-value (n=146) 
(n=58) sexuality (n= 88) 
Lack of organizational policy 67% 49% 79% <.001 
Lack of training 42% 43% 80% <.001 
Issues relating to culture and religion 40% 68% 53% .121 
Older aged patient 39% 43% 60% .084 
Issues relating to language and ethnicity 38% 56% 54% .832 
Not knowing how to initiate the subject 35% 32% 71% <.001 
Patient does not initiate the subject 35% 24% 72% <.001 
Patient is too ill to address sexual issues 35% 54% 45% .395 
Lack of knowledge 28% 23% 57% .001 
Sexuality is not seen as a problem for the 22% 53% 33% .074 patient 
Sexuality is private 19% 23% 33% .253 
Concerns about increasing patients anxiety 19% 17% 33% .078 and discomfort 
Patients lack of readiness 19% 45% 32% .225 
Presence of a third party 18% 23% 24% .906 
Not enough time 13% 19% 12% .275 
Embarrassment 10% 14% 16% .837 
Table 2. (Continued) Barriers withholding nurses who do and do not discuss sexual health with their 
patients 
Total group 
Nurses who do Nurses who do 
Barrier discuss sexuality not discuss p-value 
(n=146) 
(n=58) sexuality (n=88) 
Feeling no connection with the patient 10% 11% 15% .561 
It makes me uncomfortable 9% 5% 20% .036 
I would find it unpleasant myself 8% 2% 18% .015 
Fear of offending the patient 8% 1 1 %  12% .979 
Too large an age difference between you and 
6% 2% 1 1% .071 
the patient 
Someone else's job 3% 0% 6% .075 
Patient is of the opposite sex 1% 0% 1% .400 
Patient is of the same sex 0% 0% 0% 
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4. Discussion 
To the best of our knowledge, this is the first study of HF nurses that explores the 
preferred moment of discussing sexual health and providing sexual counseling, 
and that examines differences in barriers between those nurses who do and who 
do not assess sexual health with their patients. 
Our findings suggest that the majority of HF nurses (61 %) do not assess sexual 
health, although the HF nurses (74%) in our study do feel responsible for 
discussing sexual health with their patients and offering them sexual counseling. 
This finding is comparable with those in other studies that looked at the feelings 
of responsibility experienced by cardiac healthcare providers and the practices 
regarding sexual counseling in cardiac settings. In a European survey on the 
practice and responsibility of nurses to provide sexual counseling to cardiac 
patients, 87% of the cardiac nurses agreed that nurses have a responsibility to 
discuss sexual health. However, only 11 '1/c> of the nurses discussed the subject 
frequently with their patients. 10 Furthermore, an American study on nurses 
working with patients after a myocardial infarction and national surveys in Ireland 
and Sweden of cardiac rehabilitation centers and coronary care unit teams 
produced comparable findings. 1 1 , 14,1 6  We can conclude that the lack of discussion 
about sexual health and the lack of sexual counseling in different cardiac settings 
constitute a general problem that relates not only to HF nurses, but also other 
cardiac healthcare providers. This limited implementation of sexual counseling in 
practice may rightly be called a concern, because a considerable number of 
patients with HF experience sexual difficulties that exert a negative effect on their 
own quality of life and that of their partners.6,1 7 Patients worry about resuming 
sexual activity and are in need of education and counseling on the topic of sexual 
health.1 ,2 Furthermore, previous research indicated that patients also experience 
barriers to initiating this topic.7 
Therefore, to improve the treatment of cardiac patients, more attention needs to 
be paid to sexual counseling in nursing education. However, to educate nurses 
successfully on this subject, it is important to know which barriers keep nurses 
from assessing sexual health and providing counseling. We found that the most 
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frequently reported barrier to addressing sexual concerns was the lack of an 
organizational policy. This finding is a surprising, because HF guidelines 
recommend that healthcare providers assess sexual health with both male and 
female patients and their partners.8,9 The current class of recommendation 
assigned to this subject is "I", which indicates that counseling on sexual activity is 
considered very important. However, the results of our study suggest that HF 
clinics in The Netherlands do not pursue a policy that ensuring that patients are 
structurally educated and counseled on this subject. To improve the discussion of 
sexual health with patients, a first step could involve implementing these 
guidelines in treatment protocols. 
We found subtle differences in barriers perceived by nurses who do and nurses 
who do not discuss sexual health with their patients. Nurses who do discuss sexual 
health experience more barriers related to patient factors, such as issues related to 
culture, religion, language, ethnicity, severity of illness, and the nurses' belief that 
the patient does not see sexuality as a problem. On the other hand, nurses who do 
not discuss sexual health experience more barriers related to external factors, such 
as a lack of training, a lack of general knowledge, a lack of knowledge on how to 
initiate the topic, and the fact that the patient does not initiate the subject. In 
addition, nurses who do discuss sexual health with their patients more often 
reported to going on to higher education regarding sexual counseling. When 
considering these differences in barriers, to improve treatment, nurses may benefit 
from specific training courses to help them gain more knowledge about sexual 
health, acquire communication skills, and to feel more comfortable discussing this 
topic. 
Furthermore, it might help nurses to discuss sexual health at a moment most 
comfortable for them. According to our findings this moment occurs during a 
follow-up visit at the HF clinic, or when medication is discussed. This result 
confirms our finding that nurses working at HF clinics believe they are responsible 
for assessing sexuality; they do not delegate this task to their colleagues working at 
the rehabilitation centers. Nurses could use validated questionnaires to initiate the 
topic of sexual health, or they could try to address the topic while discussing 
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medications with the patients. 18 The moment when a medication (eg, beta­
blockers) is uptitrated provides the perfect opportunity for nurses to enquire after 
changes in sexual responses or fear of impotence. Nurses may also benefit from a 
practical workshop where they could practice the approach that would suit them 
best. Furthermore, such programs would be more helpful if they addressed the 
roles that different team members play in assessing sexuality and providing sexual 
counseling to patients. Taking these educational courses can be advantageous, 
because the improved knowledge and attitudes of nurses will help them feel at 
ease when discussing sexual health in practice. 1 9  Steinke et al. suggested a number 
of strategies that can be used in patient education and management.2° For 
example, they suggest to initiate the topic of sexual health after discussing exercise 
recommendations. To this end, they recommend using a general statement, eg, 
"Many individuals with HF have questions and concerns about resuming sexual 
activity. What concerns do you have?" In addition, Mick offered 10 strategies to 
help nurses who work with oncology patients address and validate patients' sexual 
experiences and concerns about quality of life.21 Such strategies could easily be 
translated to cardiology practice. The strategies by Mick for nurses to understand 
sexuality include providing information, addressing causes of discomfort, and 
listening objectively.21 
A limitation of this study involves the generalizability its results. We are aware of 
the fact that our study sample may be too homogenous. For instance, we sent 3 
copies of the questionnaire to all HF clinics in The Netherlands, but did not direct 
the questionnaires to the nurses personally. We expected the response to be higher 
if the questionnaires were addressed anonymously. However, as a consequence of 
this approach, we only acquired information on the demographics of nurses who 
did respond, and thus there was a lack of information on nurses who did not 
respond. Furthermore, we can reasonably expect that, for the most part, nurses 
who already have an affinity with the subject completed and returned the 
questionnaire. This could have resulted in an overrepresentation of the percentage 
of nurses who not only feel responsible for addressing the topic of sexual health, 
but who also put this responsibility into practice. Furthermore, we imagine that 
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nurses who do not recognize the importance of the subject, and who therefore do 
not feel responsible for discussing sexual health with their patients, also did not 
complete the questionnaire. Our study was also limited because we did not 
perform psychometric testing on the complete questionnaire; we only tested for 
face-validity. Although the questionnaires were previously used in a European 
population, they were not primarily developed for the Dutch population.8 
We can conclude that although nurses feel they have a responsibility to discuss 
their patients' sexual health, sexuality is rarely discussed in HF clinics. The 
preferred moment of initiating this topic occurs during a follow-up visit to the 
outpatient clinic or when medication is discussed. Barriers experienced by nurses 
to discussing sexuality are related to personal, patient and organizational factors. 
To improve patient care, interventions and training courses should focus on 
improving both nurses' knowledge about sexual health and their communication 
skills. Such educational courses should be practical and aimed at making nurses 
feel at ease discussing matters of sexuality in daily practice. The roles of different 
team members and the possibilities for referral to other professions also need to 
be taken into account. Furthermore, HF guidelines should include sexual 
counseling in the policy of organizations. 
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Summary, conclusions, and future perspectives 
The aims of this thesis were twofold: firstly, to gain more insight in the quality of 
life of patients with heart failure, more specifically those patients with heart failure 
and a preserved ejection fraction (HF-PEF), and secondly, to learn more about the 
sexual health of patients with heart failure. In recent years, studies on patient­
centred outcomes, such as quality of life, have become of great importance, 
particularly because life expectancies for patients with heart failure have increased 
and patients have to adjust to living with a chronic condition. 1,2 Fortunately, due 
to recent research on this topic, knowledge of quality of life, and more 
importantly, knowledge of how to improve quality of life of patients with heart 
failure, is increasing. Nevertheless, there are still some gaps in this research area 
that need to be addressed. Not only is the knowledge of the quality of life of 
patients with heart failure and a preserved ejection fraction (HF-PEF) limited, but 
sexual health is also rarely addressed; even though this is an important component 
of quality of life of both men and women with cardiovascular disease.3 This is 
remarkable, because about 50% of all patients with heart failure have HF-PEF,4,5 
and at least 50% of all patients with heart failure report their sexual activity has 
decreased or completely ceased as a result of their heart failure.6-9 The first part of 
this thesis looked at the prognostic value of quality of life of patients with heart 
failure, and in particular the quality of life of patients with HF-PEF. The second 
part of the thesis focused on the sexual health of patients with heart failure and 
the current practice of discussing sexuality by heart failure nurses. 
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PART I 
To examine the prognostic value ef quality ef life on lo11g-tem1 S11roival ef patients 1vith heart 
jail11re 
Main findings 
Chapter 2 showed that the quality of life of heart failure patients assessed at 
discharge from the hospital, is a predictor for 3-year mortality, independent of 
disease severity, measured by plasma B-type natriuretic peptide (BNP) levels, and a 
wide range of demographical and clinical variables. General health and physical 
functioning, assessed with a disease-generic quality of life questionnaire, can 
provide prognostic information on survival in addition to other prognostic 
variables. Patients with low scores on these dimensions were more likely to be in 
New York Heart Association (NYHA) functional class III-IV, were diagnosed 
with co-morbidities, were suffering from heart failure longer, had lower estimated 
glomerular filtration rates (eGPR's), and had fewer beta-blocker prescriptions. 
To examine the quality ef life ef patients 1vith heart fail11re and a preserved left ventricular 
'!}ection fraction in more detail 
Main findings 
Chapters 3 and 4 focused on the quality of life of patients with HF-PEF. Chapter 
3 reported that the quality of life of patients with HF-PEF and elevated plasma 
BNP levels was similarly impaired when compared with age and gender-matched 
patients with heart failure and a reduced ejection fraction (HF-REF). In Chapter 4, 
patients with a preserved ejection fraction and plasma BNP levels >100pg/ml 
were compared with patients with a preserved ejection fraction and plasma BNP 
levels <100pg/ml. Patients with a preserved ejection fraction and BNP levels 
<100pg/ml, did not differ from patients with HF-PEF and BNP levels 
> 100pg/ ml on a broad range of characteristics and HF symptoms. The former 
were, however, more often obese and in NYHA class III-IV. Furthermore, their 
quality of life was just as impaired as the quality of life of patients with HF-PEF 
and BNP levels >l 00pg/ml. Although there is a clinically relevant difference in 
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the scores indicating worse disease-generic quality of life on the physical 
functioning, general health and bodily pain dimensions for patients with BNP 
levels < 1 OOpg/ ml. 
Part I: Conclusion and discussion 
The quality of life of patients with HF-PEP, irrespective of their plasma BNP 
levels, proved to be similar to patients with HF-REF. Quality of life, in particular 
physical functioning and general health, was related to long-term survival of these 
patients. Therefore, interventions should focus on improving (physical) quality of 
life in order to improve both long-term survival and to increase patients' zest for 
living. These interventions might include offering education to patients on the 
importance of exercise, referring patients to a rehabilitation centre, and enrolling 
patients in exercise programmes. Patients can also adopt a more physically active 
lifestyle by integrating exercise in their daily activities, for instance, by taking a 
brisk walk, climbing stairs (rather than taking the lift), doing more housework, 
gardening, and engaging in active recreational pursuits.10 Several studies have 
demonstrated that exercise training is safe and can improve the quality of life of 
patients with heart failure.1 1- 13 When attending an exercise programme, an 
individualised approach that includes a clinical evaluation that takes into account 
behavioural characteristics, personal goals, and preferences is recommended. 1 4  
Individualised training protocols can vary on a number of factors: intensity 
(aerobic and anaerobic), type (endurance, resistance, and strength), method 
(continuous and intermittent/interval), application (systematic, regional, and 
respiratory muscle), control (supervised and non-supervised), and setting 
(hospital/ centre- and home-based).14,1 5  
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PART II 
To assess the prevalence ef sexual problems and related factors in patients 1vith heart failure 
Main findings 
Chapter 5 showed that almost 50% of the patients with heart failure perceived 
difficulties with sexuality at one month after hospital discharge. Thirty percent 
recovered from these difficulties during a 17-month follow-up period. However, 
about the same number of patients developed sexual problems during this period. 
Experiencing sexual difficulties was independently associated with a lower physical 
and emotional quality of life. Chapter 6 reported that, compared with healthy 
community controls, younger patients and patients with a partner experienced 
more sexual problems. Although male patients more often perceived sexual 
problems, a large number of women, older patients, and patients without a partner 
also reported sexual problems. A considerable number of patients with heart 
failure attributed their sexual problems to symptoms of heart failure, including 
dyspnoea, fatigue, and exercise intolerance. 
To describe the current practice ef dismssing sexuality l?J heart failure nurses 
Main findings 
Chapter 7 observed that the majority of the heart failure nurses felt responsible for 
discussing sexual health. However, in daily practice sexuality was rarely discussed 
with patients with heart failure. Nurses who did discuss sexuality with their 
patients more often reported that they had attended courses on sexual counselling. 
The most prominent barriers experienced by nurses who did not discuss sexual 
health were lack of an organisational policy, lack of training, not knowing how to 
initiate the subject, and the fact that patients do not initiate the topic themselves. 
Part II: Conclusion and discussion 
Chapters 5 and 6 demonstrated that a large proportion of male and female 
patients, regardless of age and marital status, reported sexual problems at 1 and 17 
months after hospital discharge. Having sexual problems was related to a lower 
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quality of life, and patients attributed these problems to their disease. This implies 
that sexual health needs to be discussed during treatment, preferably more than 
once, with both male and female patients, regardless of whether they have a 
partner. Although nurses feel they have a responsibility to discuss sexual health 
with their patients, Chapter 7 noted that in daily practice sexual health was in fact 
rarely discussed with patients with heart failure. Although these findings are 
comparable with results of previous studies on the feelings of responsibility of 
cardiac healthcare providers and the practice of discussing sexual health in cardiac 
settings, they are nevertheless remarkable. 1 6  zo Heart failure guidelines explicitly 
recommend that healthcare providers should assess sexual health with both male 
and female patients and their partners.21 ,22 Recently, a scientific statement on 
sexual activity and cardiovascular disease has been published.23 This document 
stated that approximately 60% to 87% of patients with heart failure report sexual 
problems.6-8 However, something can be done about these alarmingly high figures. 
An optimal treatment of heart failure, for instance, can increase the likelihood of 
safe and satisfactory sexual activity. Studies on stable patients with heart failure 
have shown that it is safe for such patients to engage in sexual activity.24- 27 
Furthermore, exercise training improves quality of life, and may have a positive 
impact on the sexual health of patients with heart failure as we11. 12,2s 
Critical reflection on study population and methodology 
In the previous chapters, limitations and methodological considerations specific to 
this particular study were described. In this section a critical reflection on some 
methodological issues of this thesis is presented. 
Data of patients participating in the COACH study (Coordinating study evaluating 
Outcomes of Advising and Counselling in Heart failure) were used for the studies 
described in Chapters 2 to 6.29,30 The COACH study is one of the largest of its 
kind to evaluate the role of advice and counselling in patients with heart failure. A 
total of 1 023 patients were randomized and followed for 18 months. The selection 
criteria for the patient population were broad, and the diagnosis of heart failure 
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was based on the 2001 guidelines.3 1 This resulted in a study sample of elderly 
patients with several co-morbidities, as well as patients with HF-REF and HF­
PEF, with both high and low plasma BNP levels. The heart failure study 
population is representative of the heart failure population seen in clinical practice 
and outpatient clinics. Therefore, results can be generalised to the clinical heart 
failure population. However, to minimize the at times severe impact of a recent 
hospitalization on quality of life and sexual health, data on these variables were 
used at 1 and 18 months after discharge in the studies described in Chapters 3, 4, 
5, and 6. 
The studies included in this thesis that use data of the patients participating in the 
COACH study (Chapters 2 to 6) were secondary group analyses. The COACH 
study was not primarily designed to investigate the prognostic value of quality of 
life on survival, the quality of life in patient with HF-PEF and HF-REF, and 
sexual problems in patients with heart failure. 
Implications for health care 
Improving physical functioning 
The findings of this thesis show that quality of life is low in patients with heart 
failure. Additionally, physical functioning is independently associated with 
mortality (Chapter 2) and related to sexual problems (Chapter 5). Therefore, to 
increase the quality of life and survival of these patients, improving physical 
function should form an important component of the treatment programmes for 
these patients, along with offering education on how to live with a chronic disease 
like heart failure, and helping patients set realistic goals to improve their quality of 
life in other domains than physical functioning. 
Studies have shown that exercise training improves physical functioning and 
quality of life, and reduces mortality in patients with heart failure, including 
patients with HF-PEF.20,3Z,33 In addition, the heart failure guidelines recommend 
regular physical activity and structured exercise training for these patients.20 
Unfortunately, according to a European survey, less than 20% of the patients with 
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heart failure are currently participating in a cardiac rehabilitation programme.34 In 
The Netherlands only 3.7% of the patients with heart failure is referred to a 
rehabilitation centre.35 Therefore, it is important to develop strategies that improve 
referral to cardiac rehabilitation centres. Possible strategies could include 
increasing the awareness of healthcare providers working with patients with heart 
failure about the possibility to refer patients to cardiac rehabilitation centres, the 
benefits of exercise training, and the recommendations of the guidelines. 
Furthermore, cardiac rehabilitation centres might want to inform nearby heart 
failure clinics about the exercise programmes they offer. 
Improving physical functioning: implications for healthcare providers 
Considering the importance of improving physical functioning, it is vital that 
healthcare providers working at heart failure clinics recognise which patients could 
benefit from exercise training. The guidelines recommend exercise training for 
stable patients with heart failure, who are in NYHA functional class I-III.20 
However, patients with advanced or acute heart failure may also benefit from 
exercise training after hospital admission. It might prevent them from further 
disability, and lay the foundations for the formal exercise training plan. 14  This 
means that a broad range of patients could benefit from an exercise training 
programme, particularly patients with low physical functioning. In order to single 
out patients with low physical functioning, healthcare providers could ask patients 
to complete a questionnaire on physical functioning, for example, the particular 
subscale of the RAND36 questionnaire, prior to their first visit to the heart failure 
clinic. The healthcare provider should educate all patients about the importance of 
regular exercise, and when the current level of physical functioning is low, refer 
them to a cardiac rehabilitation centre where they can obtain a suitable exercise 
programme. 
Healthcare providers should, however, keep in mind that patients who have 
depressive symptoms do not benefit from interventions.36 Therefore, it is 
important to assess depressive symptoms in addition to physical functioning, for 
example, with an interview or the CES-D questionnaire. Unfortunately, an overlap 
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exists between depressive symptoms and heart failure symptoms. To reveal the 
underlying cause, healthcare providers therefore need to discuss the results of the 
questionnaire with their patients. When the symptoms appear to be depression­
related, and not heart failure-related, in addition to improving their physical 
functioning, patents should also be referred to a psychologist. 
Discussing sexual health 
Prior studies have shown that compliance with the heart failure regimen is related 
to the knowledge patients have of heart failure and the prescribed regimen.37 
Improving knowledge by means of education and counselling remains an 
important issue in heart failure disease management programs, and a 
comprehensive nursing assessment is essential in this respect.20 This assessment 
should focus on education about the consequences of heart failure, heart failure 
symptoms, and the regimen, which includes the effect of heart failure and heart 
failure medication on sexuality. Although heart failure nurses feel responsible for 
discussing sexuality with their patients, the majority of the nurses do not assess 
sexual health in practice (Chapter 7). This limited counselling on sexuality may 
rightfully be called a concern, because a considerable number of patients with 
heart failure experience difficulties with sexuality, which in turn have a negative 
influence on their quality of life (Chapter 5). This thesis has shown that the most 
prominent barrier that keeps nurses from sexual counselling is the lack of 
organisational policy, which means that a discussion of sexual health is not 
included in the treatment protocols of heart failure clinics. This is surprising, 
because the heart failure guidelines recommend discussing sexual health with all 
male and female patients and their partners.20 Therefore, the first step towards 
improving counselling on sexual problems should include encouraging the 
management team of heart failure clinics to integrate a discussion of sexual health 
in their treatment protocol. 
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Discussing sexual health: implications for healthcare providers 
The second barrier mentioned by nurses with respect to discussing sexual health 
relates to the lack of training they experience (Chapter 7). Due to economising on 
hospital resources, nurses often suffer from cutbacks on education. However, 
nurses might benefit from an interactive course which not only focuses on 
increasing knowledge on how heart failure and medication affect sexuality, but 
also helps nurses with practical exercises on how to initiate the subject. Such a 
course enables nurses to gain knowledge, but also helps them acquire the kind of 
communication skills that will make them feel more comfortable discussing a 
sensitive subject such as sexual health. Training on how to approach a subject like 
sexual health can definitely be an incentive to nurses to start discussing sexual 
health with their patients. 
An easy way to broach the subject is by informing patients that the symptoms of 
heart failure and the medication regimen will affect many aspects of their lives, 
including sexual functioning. This creates an environment where patients feel 
more comfortable to talk about their concerns. Furthermore, the healthcare 
provider should keep in mind that a number of patients experiencing sexual 
difficulties 1 month after discharge, recovers from these difficulties during a 17 -
months follow-up period. However, around the same number of patients who did 
not experience difficulties at 1 month after discharge, develop these during the 
follow-up period (Chapter 5) . Therefore, healthcare providers should inform 
patients about the possibility to discuss sexual health more than once during the 
treatment period. 
If the treatment of the specific sexual problem lies beyond the scope of the 
healthcare provider working at the heart failure clinic, he or she should be aware 
of the possibility to refer the patient to a psychologist, sexologist, or urologist. 
Heart failure clinics could benefit from an organisation chart in which the patient 
with heart failure has a central role. By adding all healthcare providers and their 
specific expertise related to sexual problems to this chart, referral will become 
easier and less time-consuming for both the healthcare provider and the patients. 
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Implications for further research 
Patients with heart failure with preserved ejection fraction 
Pharmacological and non-pharmacological management interventions have 
proven to be successful in patients with HF-REF. They increase survival rates, 
decrease morbidity rates, and improve quality of life. Unfortunately, there are no 
treatment options for patients with HF-PEF that have proven to be effective over 
a longer period of time. Pharmacological interventions that are successful in 
patients with HF REF, for instance, have shown to be ineffective in patients with 
HF-PEF.38-41 This suggests that HF-PEF differs in pathology from HF-REF. In 
order to find a suitable medical treatment for patients with HF-PEF, it is 
important to gain insight in the definition and diagnosis of this disease. Therefore, 
future research should not only focus on successful (pharmacological and non­
pharmacological) interventions to improve survival and quality of life of patients 
with HF-PEF, but also look at the cause and development of HF-PEF and the 
interaction with high age and co-morbidities of the patients. 
Improving sexual health 
This thesis has observed that many patients with heart failure experience sexual 
problems. Future research could focus on how to improve the sexual health of 
these patients. A variety of studies have been conducted on how to treat erectile 
dysfunction in male patients with heart failure, and on the effect of 
phosphodiesterase type 5 inhibitors in these patients.42 However, there are no 
studies to date that address sexual problems in female heart failure patients, or that 
focus on other sexual problems than erectile dysfunction in patients with heart 
failure. Therefore, future research on improving sexual health in patients with 
heart failure should focus on these aspects as well. Possible research interventions 
for improving sexuality could include sexual counselling by using the PLISSIT 
(permission, limited information, specific suggestion, and intensive therapy) 
model. This model is a practical and useful tool that helps healthcare providers in 
their discussion of sexual health with their patients.43-45 
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Samenvatting en conclusies 
Het doel van dit proefschrift was om meer inzicht in de kwaliteit van leven van 
patienten met hartfalen te verkrijgen, in het bijzonder in de kwaliteit van leven van 
patienten met hartfalen en een behouden linker ventrikel ejectie fractie (heart 
failure with a preserved ejection fraction, HF-PEF). Daarnaast is er uitgebreid 
aandacht besteed aan de seksuele problemen van patienten in relatie tot hun 
hartfalen. Omdat de levensverwachting van patienten met hartfalen is 
toegenomen, en patienten moeten leren leven met een chronische aandoening, 
wordt er steeds meer belang gehecht aan studies naar patient gerelateerde 
uitkomsten.1 ,2 Door onderzoek naar dit onderwerp te verrichten is niet alleen de 
kennis over de kwaliteit van leven toegenomen, maar ook de kennis over hoe deze 
kwaliteit verbeterd kan worden bij patienten met hartfalen. Helaas is er ook nog 
veel niet bekend op dit gebied: niet alleen is de kennis over de kwaliteit van leven 
van patienten met hartfalen en een behouden ejectie fractie minimaal, maar ook 
seksuele gezondheid, toch een belangrijk onderdeel van de kwaliteit van leven van 
mannen en vrouwen met een cardiovasculaire aandoening, krijgt maar weinig 
aandacht.3 Dit mag met recht opvallend genoemd worden, omdat ongeveer 50% 
van alle patienten met hartfalen een behouden ejectie fractie heeft,4,5 en minstens 
50% van alle patienten met hartfalen rapporteert dat hun seksuele activiteiten zijn 
afgenomen of zelfs geheel gestopt zijn vanwege hun hartfalen.6 9 Het eerste deel 
van het proefschrift onderzocht de voorspellende waarde van kwaliteit van leven 
op de kans van overlijden van patienten met hartfalen, en beoogde daarnaast meer 
inzicht te krijgen in de kwaliteit van leven van patienten met een behouden ejectie 
fractie. Het tweede deel van het proefschrift richtte zich op de seksuele 
gezondheid van patienten met hartfalen en de huidige praktijk in hartfalen 
poliklinieken met betrekking tot het bespreken van seksualiteit. 
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DEEL I 
Inz!cht krijgen in de voorspellende 111aarde van k1JJaliteit van /even op de kans van overlijden op 
de lange termijn bfjpatiifnten met hartfalen 
Belangrijkste resultaten 
In hoofdstuk 2 werd aangetoond dat kwaliteit van leven, gemeten bij ontslag na 
een ziekenhuisopname voor hartfalen, een voorspellende waarde heeft in relatie 
tot de kans op overlijden binnen 3 jaar na ontslag, onafhankelijk van de ziekte­
ernst, gemeten met bloedwaarden van B-type natriuretic peptide (BNP), en een 
groot aantal demografische en klinische variabelen. Vooral de algemene 
gezondheid en het fysieke functioneren, gemeten met een ziektegenerieke kwaliteit 
van leven vragenlijst, bleken een voorspellende waarde te hebben ten aanzien van 
overlijden, aanvullend op andere voorspellende factoren. Patienten met een lage 
score op deze subschalen waren vaker ingedeeld in New York Heart Association 
(NYHA) klasse III-IV, waren vaker gediagnosticeerd met comorbiditeiten, waren 
sinds langere tijd bekend met de diagnose hartfalen, hadden lagere estimated 
glomerular filtration rates (eGFR's), en kregen minder vaak betablokkers 
voorgeschreven. 
Inz!cht krijgen in de k111aliteit van /even van patiinten met hartfalen en een behouden efectie 
Jractie 
Belangrijkste resultaten 
In hoofdstuk 3 en hoofdstuk 4 werd gekeken naar de kwaliteit van !even van 
patienten met hartfalen en een behouden ejectie fractie. Hoofdstuk 3 maakte 
duidelijk dat de kwaliteit van leven van patienten met een behouden ejectie fractie 
(heart failure with a preserved ejection fraction, HF-PEF) en verhoogde BNP­
waarden, even slecht is als de kwaliteit van !even van patienten met een verlaagde 
ejectie fractie (heart failure with a reduced ejection fraction, HF-REF), waarbij 
beide groepen gematched zijn op leeftijd en geslacht. In hoofdstuk 4 werd een 
groot aantal demografische kenmerken, klinische kenmerken, en indicatoren van 
kwaliteit van leven van patienten met HF-PEF en BNP-waarden hoger dan 
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1 00pg/ml vergeleken met pat1enten met HF-PEF en BNP-waarden lager clan 
1 00pg/ml. Patienten met HF-PEF en BNP-waarden lager clan 1 00pg/ml bleken 
niet te verschillen van patienten met HF-PEF en BNP-waarden hoger clan 
1 00pg/ml, behalve clan dat de patienten met BNP-waarden lager clan 100pg/ml 
vaker obees waren, en vaker waren ingedeeld in NYHA klasse III-IV. Daarnaast 
ervoeren beide groepen hun kwaliteit van leven als even slecht, hoewel er wel een 
klinisch relevant verschil in de scores viel uit te maken, wat duidde op een 
slechtere kwaliteit van leven van patienten met lagere BNP-waarden ten aanzien 
van de dimensies van fysiek functioneren, algemene gezondheid, en pijn. 
Deel I: Conclusie en discussie 
De kwaliteit van leven van patienten met hartfalen en een behouden ejectie fractie, 
ongeacht de hoogte van hun BNP-waarden, bleek even slecht te zijn als de 
hvaliteit van leven van patienten met hartfalen en een verlaagde ejectie fractie. 
Kwaliteit van leven, in het bijzonder de dimensies fysiek functioneren en algemene 
gezondheid, is gerelateerd aan een grotere kans op overlijden op de lange termijn 
bij deze patienten. Om deze reden is het belangrijk dat interventies bij deze 
patienten zich richten op het verbeteren van de (fysieke) kwaliteit van leven. 
Hiermee wordt niet alleen de kans op overlijden verlaagd, maar krijgen patienten 
ook meer plezier in het leven. Voorbeelden van interventies op dit gebied zijn het 
geven van voorlichting over het belang van bewegen, het tijdig doorverwijzen 
naar een revalidatiecentrum, en het aanbieden van een op maat gesneden 
bewegingsprogramma. Patienten kunnen zichzelf ook een fysiek actievere 
levensstijl aanleren door bewegen te integreren in hun dagelijkse bezigheden, zoals 
stevige wandelingen maken, zoveel mogelijk de trap nemen (in plaats van de lift), 
meer huishoudelijke taken verrichten, tuinieren, en deelnemen aan recreatieve 
activiteiten die een flinke fysieke inspanning verlangen. 10 Onderzoek heeft 
aangetoond dat fysieke training veilig is en de kwaliteit van leven van patienten 
met hartfalen kan verbeteren. 1 1 - 13 Bij deelname aan een bewegingsprogramma is 
het sterk aan te raden om te kiezen voor een individuele benadering waarbij een 
klinische evaluatie 1s inbegrepen, welke onder andere gericht 1s op 
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gedragskenmerken, persoonlijke doelen en voorkeuren. 1 4  Individuele 
trainingsprogramma's kunnen verschillen ten aanz1en van diverse factoren: 
intensiteit (aerobisch en anaerobisch), soort (uithoudingsvermogen, 
weerstandsvermogen, en kracht), methode (continu en met tussenpozen/interval), 
doel (systematisch, regionaal, en gericht op de ademhalingsspieren), controle (met 
en zonder supervisie), en setting (ziekenhuis, bij een instelling en thuis) . 14, 1 5  
DEEL II 
Inzjcht knjgen in de preva/entie van seks11ele proble111e11 en de daar1JJee gerelateerde factoren bij 
patiei1ten met harifale11 
Belangrijkste resultaten 
In hoofdstuk 5 werd aangetoond dat bijna 50% van de patienten met hartfalen een 
maand na ontslag uit het ziekenhuis problemen met seksualiteit ervoer. Dertig 
procent herstelde van deze problemen gedurende een follow-up periode van 1 7 
maanden. Echter, tijdens deze periode ontstonden bij ongeveer hetzelfde aantal 
patienten seksuele problemen. Het ervaren van seksuele problemen was 
onafhankelijk gerelateerd aan een lagere fysieke en emotionele kwaliteit van leven. 
Hoofdstuk 6 liet zien dat, vergeleken met een groep gezonde personen, jongere 
patienten en patienten met een partner vaker problemen met seksualiteit ervoeren. 
Hoewel mannelijke pat1enten vaker seksuele problemen ondervonden, 
rapporteerden ook een groat aantal vrouwen, oudere patienten, en patienten 
zonder partner seksuele problemen. Een groot aantal patienten met hartfalen 
schreef hun problemen toe aan de symptomen van hartfalen, zoals 
kortadernigheid, vermoeidheid, en een verrninderd uithoudingsvermogen. 
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Het beschrijven van de huidige praktijk rondom het bespreken van seksualiteit door hartfalen 
ve,pleegk1mdige11 
Belangrijkste resultaten 
In hoofdstuk 7 kwam naar voren dat een meerderheid van de hartfalen 
verpleegkundigen zich verantwoordelijk voelt voor het bespreken van de seksuele 
gezondheid van hun patienten. Desondanks werd seksualiteit in de dagelijkse 
praktijk zelden besproken met patienten met hartfalen. Verpleegkundigen die het 
onderwerp seksualiteit wel bespraken met hun patienten, rapporteerden vaker dat 
ze een aanvullende opleiding hebben gevolgd specifiek gericht op seksuele 
counseling. Verpleegkundigen die seksualiteit niet bespraken noemden een aantal 
barrieres waar ze tegenaan liepen; deze varieerden van organisatorische factoren 
(het beleid van de instelling is niet gericht op het bespreken van seksualiteit en er is 
een gebrek aan trainingen op dit gebied), tot communicatiegerichte factoren 
(onzekerheid over hoe het onderwerp aan te snijden en dat patienten zelf niet over 
het onderwerp beginnen). 
Deel II: Conclusies en discussie 
De resultaten van hoofdstuk 5 en hoofdstuk 6 toonden aan dat een groat deel van 
de mannelijke en vrouwelijke patienten, oudere en jongere patienten, en patienten 
met en zonder partner na 1 en na 1 7  maanden na ontslag uit het ziekenhuis 
problemen met hun seksualiteit ondervonden. Het ervaren van seksuele 
problemen is gerelateerd aan een lagere kwaliteit van leven, en patienten schrijven 
hun problemen toe aan hun ziekte. Daarom is het van groat belang dat de seksuele 
gezondheid van patienten met hartfalen besproken wordt gedurende de 
behandeling, bij voorkeur meerdere malen, met zowel mannelijke en vrouwelijke 
patlenten, ongeacht hun relatiestatus (wel of geen partner). Hoewel 
verpleegkundigen zich wel verantwoordelijk voelen voor het bespreken van 
seksualiteit met hun patienten, liet hoofdstuk 7 zien dat in de dagelijkse praktijk 
seksualiteit zelden besproken wordt met patienten met hartfalen. Ondanks het feit 
dat deze resultaten vergelijkbaar zijn met de resultaten van eerdere studies naar de 
verantwoordelijkheid die hulpverleners ervaren, en de praktijk met betrekking tot 
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het bespreken van seksualiteit op cardiologische afdelingen, zijn ze toch opvallend 
te noemen. 1 6  20 Richtlijnen voor de behandeling van hartfalen raden hulpverleners 
namelijk aan om seksualiteit met zowel mannelijke als vrouwelijke patienten en 
hun partners te bespreken.2 1 ,22 Onlangs is er een wetenschappelijke verklaring 
gepubliceerd over seksualiteit en cardiovasculaire aandoeningen.23 Uit deze 
verklaring blijkt dat maar liefst 60% tot 87% van de patienten met hartfalen 
seksuele problemen rapporteren.6 8 Gelukkig kan hier iets aan gedaan worden. Een 
optimale behandeling van hartfalen vergroot namelijk de kans op veilige en 
bevredigende seksuele activiteiten. Onderzoek bij stabiele patienten met hartfalen 
toont aan dat het voor deze patienten veilig is om seksueel actief te zijn.24 27 
Daarnaast vergroot fysieke training de kwaliteit van leven, en heeft het mogelijk 
ook een positief effect op de seksuele gezondheid van patienten met hartfalen. 12,28 
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In februari 2009 ben ik begonnen met mijn promotieonderzoek bij de 'COACH­
groep' op de afdeling Cardiologie van het Universitair Medisch Centrum 
Groningen. Nu, bijna 4 jaar later, is het proefschrift clan oak daadwerkelijk 
afgerond. Ik kijk met veel plezier terug op een zeer leerzame periode, en ben ik erg 
dankbaar voor de kans die ik heb gekregen om mijn promotieonderzoek uit te 
kunnen voeren bij de afdeling Cardiologie van het UMCG. 
Ik ben zeer tevreden met het eindresultaat, en had dit niet voor elkaar kunnen 
krijgen zonder de bijdrage van een groat aantal mensen in mijn omgeving, want 
promoveren doe je niet alleen. Daarom wil ik hen hierbij bedanken. 
Als eerste mijn copromotor dr. I. Lesman-Leegte. Beste Ivonne, jij hebt mij van 
het begin tot het einde van het promotietraject begeleid. Ik kon altijd op je 
rekenen als ik er niet uit kwam met de discussie van een artikel, als ik moedeloos 
werd van de zoveelste versie van een manuscript, en toen ik voor het eerst in het 
buitenland een presentatie moest geven. Jouw nuchtere kijk op de zaken, je 
gestructureerde aanpak en je beargumenteerde commentaar hebben mij er de 
afgelopen jaren door heen geholpen. Ik was jouw eerste promovendus, maar ik 
had me geen betere copromotor kunnen voorstellen! Heel erg bedankt voor je 
betrokkenheid, je betrouwbaarheid en je begeleiding. 
Mijn promotor prof. dr. D.J. van Veldhuisen. Beste Dirk Jan, ik ben je zeer 
dankbaar voor de mogelijkheid dat ik, als psycholoog, onderzoek naar de kwaliteit 
van leven en seksuele problemen bij patienten met hartfalen op jouw afdeling 
mocht uitvoeren. Ik heb heel veel van je geleerd, van je grote wetenschappelijk 
inzicht, je resultaat gerichtheid, en van het denken en schrijven vanuit de 'take­
home-message'. Ik wil je bedanken voor je altijd snelle reacties op mijn artikelen, 
en je concrete commentaar. 
Mijn promotor prof. dr. T. Jaarsma. Beste Tiny, ik weet nag heel goed dat ik na 
mijn eerste sollicitatiegesprek met jou enthousiast over de functie, over het 
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onderzoek en over de mogelijkheden de kamer uit liep. Alie gesprekken die daar in 
de afgelopen jaren op volgden, hadden precies hetzelfde effect op mij. Ik 
bewonder je enthousiasme en je positieve kijk op de zaken, dit werkt zeer 
aanstekelijk waardoor elke dip na een gesprek met jou volledig was verdwenen en 
omgebogen naar nieuwe kansen en wegen. Ik heb veel van je geleerd, van je 
doorzettingsvermogen, van je inzichten, van je kritische (maar nooit negatieve) 
feedback, je stimulerende houding. Ik ben je heel dankbaar dat je mijn promotor 
wilde blijven, ook nadat je het UMCG verlaten had voor de functie van professor 
bij Linkoppings Universitet. En ik dank je in het bijzonder dat je mij de kans hebt 
gegeven om bij jou in Zweden intensief met je samen te mogen werken. Ik heb 
daar een fantastische en zeer leerzame tijd gehad, het was een ervaring die ik nooit 
zal vergeten. 
l'vlijn promotor prof. dr. R. Sanderman. Beste Robbert, ik heb het erg gewaardeerd 
dat je vanuit de Medische Psychologie mijn promotor wilde zijn, dat je je hebt 
verdiept in de cardiologische onderwerpen van mijn proefschrift, en daar altijd 
vernieuwende inzichten vanuit je eigen vakgebied aan toe wist te voegen. Je hebt 
me geleerd om als onderzoeker bij het interpreteren van de data, de patient zelf 
niet uit het oog te verliezen. Ik wil je bedanken voor de altijd waardevolle bijdrage 
die je hebt geleverd aan mijn artikelen en aan mijn leerproces de afgelopen jaren. 
De ]eden van de beoordelingscommissie, prof. dr. A.V. Ranchor, prof. dr. 
J .W.M.G. Widdershoven en prof. dr. H.B.M. van de Wiel, wil ik bedanken voor 
het doornemen van mijn proefschrift. 
Aile co-auteurs van mijn artikelen wil ik bedanken voor hun bijdrage aan dit 
proefschrift. 
1-fijn collega's van de COACH groep wil ik bedanken voor de samenwerking en 
jullie feedback bij de (oefen)presentaties, het bespreken van de artikelen en 
natuurlijk de gezellige momenten tijdens teamuitjes, borrels en congressen! Martje, 
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Marie Louise en Ivonne, bedankt voor jullie expertise als teamleiders. Jullie zijn bet 
COACH team van bet eerste uur, en hebben alle 'ins' en 'outs' van bet COACH 
tijdperk voor ons met ons gedeeld. Arjen, Imke, Maaike en Maurice, jullie 
zaten/ zitten in bet zelfde schuitje als ik, met dezelfde stress maar ook met 
dezelfde overwinningsmomenten, die we samen hebben kunnen vieren. Dank 
jullie allemaal voor de afgelopen jaren, zonder jullie was bet niet zo leerzaam, maar 
vooral ook niet zo gezellig geweest. 
Alma, ik wil je heel erg bedanken voor al je hulp tijdens, maar vooral ook in de 
laatste fase van bet promotietraject. Jij wist mij altijd duidelijk te maken wat de 
volgende stap was, als ik door de bomen bet bos niet meer zag. Audrey, ook 
bedankt voor jouw hulp. 
Prof. dr. Hans Hillege en dr. Douwe Postmus wil ik bedanken voor de statistische 
ondersteuning. De mede promovendi op de 'eerste' wil ik bedanken voor de 
gezelligheid op de congressen. De collega's van cardio research wil ik bedanken 
voor de betrokkenheid en praatjes op de gang. In bet bijzonder wil ik Margriet 
bedanken voor de gezelligheid tijdens onze ritjes naar de patienten in heel 
Nederland, en de samenwerking bij het afnemen van de patienten interviews en de 
dataverzameling voor bet project over het bespreken van seksualiteit. 
Familie en vrienden, ik wil jullie bedanken voor jullie oprechte belangstelling en 
interesse in mijn onderzoek, maar natuurlijk ook voor de gezellige momenten en 
jullie begrip en steun op de moeilijke momenten: Marrit, Jelmer, Theo, Wietske, 
Sylke, Yorrit, Brent, Joke, Gerda, Jacoba, Fiona, Joletta, Gillian, Jaap, Thessa, 
Petra, Wijnand, Rutger, Annemarie, Jeroen, Guido, Linda, Shelley, Corine, en 
natuurlijk mijn Twister vrienden; de maandag werd een dag om naar uit te kijken 
sinds ik met j ullie theatersport: Eva, Gea, Geert Jan, Hanneke, Jan, Johan, 
Marianne, Mariano en Peter. 
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Mijn paranimfen Maurice Nieuwenhuis en Johan Pijlman. Beste Maurice, we zijn 
vrijwel gelijk begonnen met ons promotie traject bij de COACH groep, en sluiten 
het vrijwel gelijk af. Gedurende die periode ben je naast een collega en 
kamergenoot ook een goede vriend geworden. We hebben veel gedeeld, moeilijke 
en serieuze momenten, maar vooral ook veel geweldige momenten. We hebben 
veel gelachen, samen muziek gemaakt tot in de late uurtjes, en jij hebt me doen 
inzien dat voetbal meer is clan een spelletje, omdat je alle situaties in het leven met 
voetbal kunt vergelijken. Dank je wel voor een geweldige tijd! 
Beste Johan, jij bent al sinds de vijfde klas van het VWO een goede vriend van mij. 
Nederlands, aardrijkskunde en economie werden ineens leuke vakken, omdat ik 
clan naast jou zat. We hebben veel gedeeld, destijds, maar ook alle jaren daarna. Na 
het VWO ging jij in Groningen studeren en ik in Leiden. We hebben altijd contact 
gehouden, en zagen elkaar weer wat vaker toen ik na jaren alsnog naar Groningen 
verhuisde. Maar ongeacht of het contact nou wel of niet intensief was, het was 
voor mij altijd vertrouwd. Dank je wel voor je jarenlange vriendschap! 
Tenslotte, mijn ouders, leave heit en mem, tank jim wol foar jim leafde sunder 
betingst. Jim haw altyd efter myn kar stien, en stean altyd klear foar my. Ik bin jim 
hiel tankber foar alles wit jim my haw jun en bybrocht, en dat de doar nei jimme 
feiliche en waarme thus altyd iepen stiet. 
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De NHS-COACH studie (Nederlandse Hartstichting - Coordinating study on 
evaluating Outcomes of Advising and Counseling in Heart failure) is uitgevoerd in 
17 ziekenhuizen in Nederland. Zander de financiering van de Nederlandse 
Hartstichting en de grate inzet van velen was de COACH-studie niet tot stand 
gekomen, en had dit proefschrift er niet gelegen. Ten eerste wil ik het COACH 
onderzoeksteam (dr. Jochem Hogenhuis, dr. Ivonne Lesman-Leegte, dr. Marie 
Louise Luttik en dr. Martje van der Wal) en alle medewerkers van het Trial 
Coordination Center Groningen bedanken (waaronder prof. dr. Hans Hillege, dr. 
Nick Veeger en ing. Marco Assmann). Dankzij jullie inspanning is er een prachtige 
databank tot stand gekomen. Verder wil ik een ieder die in de centra heeft 
meegewerkt; hartfalenverpleegkundigen, cardiologen en interviewers, maar ook de 
medewerkers van de laboratoria en deelnemers aan het multidisciplinair overleg, 
langs deze weg hartelijk danken voor hun inzet: 
Universitair Meclisch Centrum Groningen 
Hartfalenverpleegkundigen: drs. A. K.oops, A. Klungel, K. van Dijk, G. Westra 
Cardiologen: prof. dr. D.J. van Veldhuisen, prof. dr. A.A. Voors 
Dataverzamelaars: G. Feringa, A. Schwencke, L. Grevink, K. Bruggink 
Academisch Meclisch Centrum, Amsterdam 
Hartfalenverpleegkundigen: T. Veelenturf, R. Zwart, S. de Vries 
Cardiologen/ artsen: prof. dr. J.G.P. Tijssen, dr. W. Kok, dr. L.M. K.onst, dr. J .  van 
der sloot 
Dataverzamelaars: L. IJzerman, R. Zuidervaart, E. Spoelstra, S. Stultiens 
Universitair Meclisch Centrum St. Radbout, Nijmegen 
Hartfalenverpleegkundigen: L. K.nubben, L. Baltussen 
Cardiologen: prof. dr. F. Verheugt, drs. L. Bellersen 
Dataverzamelaars: J. de Natris, drs. L. Hogenhuis 
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Medisch Centrum Leeuwarden 
Hartfalenverpleegkundigen: A. Obbema, A. Rijenga, D. van der Woude, J. de 
Bruin 
Cardiologen: drs. C.J. de Vries, drs. R. Breed veld 
Dataverzamelaars: A. Jonkman, C. Wassenaar 
Twenteborg Ziekenhuis, Almelo 
Hartfalenverpleegkundigen: E. Rodijk, M. Samsen, B. Beverdam, L. Bogemann 
Cardioloog: dr. G.C.M. Linssen 
Dataverzamelaars: H. Hondebrink, A. Disberg, M. Slaghekke 
Atrium Medisch Centrum, Heerlen 
Hartfalenverpleegkundigen: T. Thuis, I. Kremer, V. Post, S. Jongen 
Cardioloog: dr. J .A. Kragten 
Dataverzamelaars: drs. S. Hogenhuis, drs. E. Gaasbeek, drs. C. Beumer, B. Hoen 
J eroen Bosch Ziekenhuis, Den Bosch 
Hartfalenverpleegkundigen: D. Jaftoran, V. van Zonsbeek, A. Berkhout 
Cardioloog: dr. M.C.G. Daniels 
Dataverzamelaars: I. Samshuizen, D. Oosterkerk 
Rijnstate Ziekenhuis, Arnhem 
Hartfalenverpleegkundigen: drs. M. Rolfes, P. Nienaber 
Cardioloog: dr. F.F. Willems 
Dataverzamelaars: J. de Natris, M. Hubertus, drs. L. Hogenhuis, E. Eleveld 
Amphia Ziekenhuis, Breda 
Hartfalenverpleegkundigen: N. Creemer, I. Lauwerijssen, C. Paes 
Cardioloog: dr. P.H.J.M. Dunselman 
Dataverzamelaars: J. Hendriks, A. Lotstra, K. Terlaak 
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Refaja Ziekenhuis, Stadskanaal 
Hartfalenverpleegkundigen: D. Thoma, R. Niewold, M. Wijbenga 
Cardiologen: dr. L. van Wijk, Dr. K. de Vries 
Dataverzamelaars: S. Vennik, drs. E. Prins 
Tweesteden Ziekenhuis, Tilburg 
Hartfalenverpleegkundigen: E. Hendriks, H. Broers 
Cardioloog: prof. dr. J. Widdershoven 
Dataverzamelaars: K. Janssen, B. de Kruijf, K. de Beer 
Streekziekenhuis Midden Twente, Hengelo 
Hartfalenverpleegkundigen: L. Odink, P. ter Horst, W. Wolters, L. Navis 
Cardioloog: drs. A. Derks 
Dataverzamelaars: J. Bijen, I. Horstman, A. Ottenhof, W. Bakker, B. Nijhuis 
Scheper Ziekenhuis, Emmen 
Hartfalenverpleegkundigen: A. Bakker, W. Veenstra, J.W. van Brake! 
Cardioloog: dr. M.J. Nagelsmit 
Dataverzamelaars: J. Kruimink, J. Pool, R. de Heus 
Medisch Spectrum Twente, Enschede 
Hartfalenverpleegkundigen: J. Roukema, H. Glazenburg, J. Grooters 
Cardioloog: dr. P. van der Burgh 
Dataverzamelaars: T. Meijer, H. Vroom, J. Poggenklas 
Wilhelmina Ziekenhuis, Assen 
Hartfalenverpleegkundigen: R. Aardema, J. Veninga 
Cardioloog: dr. M.L. Pencinga 
Dataverzamelaars: E. Tiemes, E. de Vos, N. van der Linden, E. Voois 
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Deventer Ziekenhuis, Deventer 
Hartfalenverpleegkundigen: J. Burger, D. Pruijsers 
Cardioloog: drs. D.J.A. Lok 
Dataverzamelaars: L. Schoterman, M. van Buijsen, M. Scholten, H. Verheij 
Oosterschelde Ziekenhuis, Goes 
Hartfalenverpleegkundigen: J .  Witkam, A. Roelse, E. Salawanei 
Cardioloog: dr. A.H. Liem 
Dataverzamelaars: A. Remijn, M. Franse, E. Wijs 
Steeringcommittee 
Prof. dr. D.J. van Veldhuisen (Voorzitter) 
Prof. dr. T. Jaarsma 
Dr. P.H.J.M. Dunselman 
Prof. dr. W.H. van Gilst 
Prof. dr. H.L. Hillege 
Prof. dr. A.W. Hoes 
Drs. D.J.A. Lok 
Prof. dr. R. Sanderman 
Dr. M.C.M. Senten 
Dr. A. Speksnijder / Drs. I. Kamerling 
Prof. dr. J.G.P. Tijssen 
Eindpuntencommissie 
Dr. C.M.H.B. Lucas (voorzitter) 
Dr. J .H. Corne! 
Dr. R.W.M.M. Jansen 
Dr. F.H. Rutten 
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Curriculum Vitae 
Tialda Hoekstra werd geboren op 23 november 1 979 te Heerenveen. Ze is 
opgegroeid in Joure, en behaalde in 1999 haar VWO diploma aan het Bornego 
College te Heerenveen. Van 1 999 tot 2001 studeerde zij Bio-farmaceutische 
Wetenschappen aan de Universiteit Leiden, en behaalde haar propedeuse. 
Vervolgens startte zij met de studie Psychologie aan de Universiteit Leiden. 
Binnen deze studie deed zij haar afstudeer onderzoek op de afdeling 
Neuropsychologie in het Leids Universitair Medisch Centrum, naar het 
ontwikkelen van een instrumentarium om amnesie na electro shock therapie bij 
depressie te meten. Haar praktijkstage liep ze op de afdeling Neuropsychologisch 
Onderzoek bij Parnassia te Den Haag. In januari 2006 behaalde zij haar doctoraal 
diploma met als afstudeertraject Neuropsychologie, binnen de afstudeerrichting 
Klinische- en Gezondheidspsychologie. 
Na het afronden van de studie psychologie, bleef zij, aansluitend op haar 
praktijkstage, werkzaam als neuropsycholoog op de afdeling Neuropsychologisch 
Onderzoek bij Parnassia te Den Haag. Later dat jaar maakte zij de overstap naar 
de functie van onderzoeker bij de Divisie Forensische Psychiatrie van GGZ 
Drenthe te Assen. Hier bleef zij tot begin 2009 werkzaam, en verrichtte ze 
wetenschappelijk onderzoek naar onder andere de behandeleffecten van diverse 
behandelingen die binnen de Divisie werden aangeboden. 
In februari 2009 werd zij als onderzoeker aangesteld op de afdeling Cardiologie 
van het Thoraxcentrum binnen het Universitair Medisch Centrum Groningen. 
Haar onderzoek was voornamelijk gericht op de kwaliteit van leven en seksuele 
problemen bij patienten met hartfalen, met dit proefschrift als resultaat. Bij haar 
onderzoek maakte ze onder andere gebruik van de data van de COACH studie, 
welke door de Nederlandse Hartstichting werd gefinancierd. 

